Abstract
Solid organ transplantation has transformed the lives of many children and adults by providing treatment for patients with organ failure who would have otherwise succumbed to their disease. The first successful transplant in 1954 was a kidney transplant between identical twins, which circumvented the problem of rejection from MHC incompatibility. Further progress in solid organ transplantation was enabled by the discovery of immunosuppressive agents such as corticosteroids and azathioprine in the 1950s and ciclosporin in 1970. Today, solid organ transplantation is a conventional treatment with improved patient and allograft survival rates. However, the challenge that lies ahead is to extend allograft survival time while simultaneously reducing the side effects of immunosuppression. This is particularly important for children who have irreversible organ failure and may require multiple transplants. Pediatric transplant teams also need to improve patient quality of life at a time of physical, emotional and psychosocial development. This review will elaborate on the long-term outcomes of children after kidney, liver, heart, lung and intestinal transplantation. As mortality rates after transplantation have declined, there has emerged an increased focus on reducing longer-term morbidity with improved outcomes in optimizing cardiovascular risk, renal impairment, growth and quality of life. Data were obtained from a review of the literature and particularly from national registries and databases such as the North American Pediatric Renal Trials and Collaborative Studies for the kidney, SPLIT for liver, International Society for Heart and Lung Transplantation and UNOS for intestinal transplantation.
Survival; Morbidity; Cardiovascular; Kidney Function; Quality Of Life
INTRODUCTION
Patient survival after transplantation has improved substantially over the last decades. For
example, 5-year survival for deceased donor renal transplantation increased from 91% in the
1987-1995 era to 96% in the 1996-2007 era (11. North American Pediatric Renal Trials and Collaborative Studies. 2011 Annual
Transplant Report. [30 October 2013]; Available from:
https://web.emmes.com/study/ped/annlrept/annualrept2011.pdf.
https://web.emmes.com/study/ped/annlrept...
). The published
data on patient and allograft survival rates for children after kidney, liver, heart, lung and
intestinal transplantation are summarized in Table 1.
Patient and allograft survival of children after kidney, liver, heart, lung and intestinal transplantation. Living Donor, Deceased Donor.
Improvements have mainly occurred in the peri-operative period and have been attributed to better
surgical and micro-anastomosis techniques, improved donor procurement and matching schemes and
advanced HLA testing methods. HLA typing is now more precisely performed by direct DNA sequencing,
and HLA antibodies are detected through flow cytometric bead-based technology (22. Picascia A, Infante T, Napoli C. Luminex and antibody detection in kidney
transplantation. Clin Exp Nephrol. 2012;16(3):373-81,
http://dx.doi.org/10.1007/s10157-012-0635-1.
http://dx.doi.org/10.1007/s10157-012-063...
). Flow cytometry has the advantage of being highly sensitive and enables the
prediction of alloimmune responses before transplantation, which can be utilized in virtual
cross-matching. This technology also enables the detection of alloantibodies synthesized de
novo after transplantation. However, there are concerns that modern bead-based techniques
may be too sensitive and identify non-clinically relevant antibodies because of differences in the
conformation of the antigen between the beads in vitro and the actual in
vivo protein structure (22. Picascia A, Infante T, Napoli C. Luminex and antibody detection in kidney
transplantation. Clin Exp Nephrol. 2012;16(3):373-81,
http://dx.doi.org/10.1007/s10157-012-0635-1.
http://dx.doi.org/10.1007/s10157-012-063...
). Regardless, the
incidence of hyper-acute rejection resulting from pre-formed antibodies is now very low.
Transplantation in infants requires special consideration because of the mismatch in donor and
recipient size and because the indications, such as congenital abnormalities of the kidney and
urinary tract for renal transplantation, biliary atresia for liver transplantation and congenital
heart disease for cardiac transplantation, are specific to children. Transplantation in infants is
also associated with decreased patient and allograft survival rates. In renal transplantation, the
overall patient survival rate is 93% at 3 years compared with 96-99% for older children receiving
deceased donor transplants, although the difference is not as large for living donor transplants
(11. North American Pediatric Renal Trials and Collaborative Studies. 2011 Annual
Transplant Report. [30 October 2013]; Available from:
https://web.emmes.com/study/ped/annlrept/annualrept2011.pdf.
https://web.emmes.com/study/ped/annlrept...
). However, if they survive the immediate post-operative
period, infants exhibit comparable outcomes to older children.
A recent development that has increased organ availability is transplantation across the ABO
blood group barrier. The Paediatric Heart Transplant Study database of 931 ABO-incompatible cardiac
transplants performed in recipients less than 15 months old reported reduced rejection and no
differences in mortality (33. Henderson HT, Canter CE, Mahle WT, Dipchand AI, LaPorte K, Schechtman KB, et al.
ABO-incompatible heart transplantation: analysis of the Pediatric Heart Transplant Study (PHTS)
database. J Heart Lung Transplant. 2012;31(2):173-9,
http://dx.doi.org/10.1016/j.healun.2011.11.013.
http://dx.doi.org/10.1016/j.healun.2011....
). In a small single-center study
of liver transplantation for infants under 5 kg, survival was comparable to ABO-compatible
transplants (44. Gelas T, McKiernan PJ, Kelly DA, Mayer DA, Mirza DF, Sharif K. ABO-incompatible
pediatric liver transplantation in very small recipients: Birmingham's experience. Pediatr
Transplant. 2011;15(7):706-11, http://dx.doi.org/10.1111/j.1399-3046.2011.01541.x.
http://dx.doi.org/10.1111/j.1399-3046.20...
). Infancy is considered to be an
immune-privileged time for transplantation because infants have a less-developed immune system and
higher acceptance of ABO mismatches. In older children, antibody removal using, for example, plasma
exchange and rituximab, can be utilized to decrease blood group antibody levels to acceptable levels
(aiming for a dilution ratio of 1:8) (55. Barnett AN, Hudson A, Hadjianastassiou VG, Marks SD, Reid CJ, Maggs TP, et al.
Distribution of ABO blood group antibody titers in pediatric patients awaiting renal
transplantation: implications for organ allocation policy. Transplantation. 2012;94(4):362-8,
http://dx.doi.org/10.1097/TP.0b013e31825b7608.
http://dx.doi.org/10.1097/TP.0b013e31825...
). In a series of 52
consecutive kidney transplants, Shishido et al. reported no differences in glomerular filtration
rates (GFRs) or patient and allograft survival rates compared with ABO-compatible transplants (66. Shishido S, Hyodo YY, Aoki Y, Takasu J, Kawamura T, Sakai KK, et al. Outcomes of
pediatric ABO-incompatible kidney transplantations are equivalent to ABO-compatible controls.
Transplant Proc. 2012;44(1):214-6,
http://dx.doi.org/10.1016/j.transproceed.2011.12.017.
http://dx.doi.org/10.1016/j.transproceed...
). The levels of blood group antibody titers remained low after
transplantation, which suggests a degree of accommodation towards blood group glycoproteins. In
ABO-incompatible liver transplantation, a recent meta-analysis also revealed similar patient and
allograft outcomes compared with ABO-compatible patients (77. Wu J, Ye S, Xu X, Xie H, Zhou L, Zheng S. Recipient outcomes after
ABO-incompatible liver transplantation: a systematic review and meta-analysis. PloS one.
2011;6(1):e16521, http://dx.doi.org/10.1371/journal.pone.0016521.
http://dx.doi.org/10.1371/journal.pone.0...
).
It is particularly difficult to perform transplantation in sensitized patients with positive
cross-matches who exhibit positive preformed HLA antibodies. This is often expressed as the
percentage of panel-reactive antibodies (PRA), which is tested against a set HLA panel, or the
calculated reaction frequency (cRF), which uses the value for the specific HLA antibody calculated
against the known population frequency (88. Asante-Korang A, Jacobs JP, Ringewald J, Carapellucci J, Rosenberg K, McKenna D,
et al. Management of children undergoing cardiac transplantation with high Panel Reactive
Antibodies. Cardiol Young. 2011;21 Suppl 2:124-32,
http://dx.doi.org/10.1017/S1047951111001703.
http://dx.doi.org/10.1017/S1047951111001...
). A high PRA or cRF
value limits the availability of donors because patients with persistently positive HLA are excluded
from the donor pool. These patients also exhibit lower allograft and patient survival rates and
higher rates of allograft rejection after transplantation (99. Mahle WT, Tresler MA, Edens RE, Rusconi P, George JF, Naftel DC, et al.
Allosensitization and outcomes in pediatric heart transplantation. J Heart Lung Transplant.
2011;30(11):1221-7, http://dx.doi.org/10.1016/j.healun.2011.06.005.
http://dx.doi.org/10.1016/j.healun.2011....
,1010. Wright EJ, Fiser WP, Edens RE, Frazier EA, Morrow WR, Imamura M, et al. Cardiac
transplant outcomes in pediatric patients with pre-formed anti-human leukocyte antigen antibodies
and/or positive retrospective crossmatch. J Heart Lung Transplant. 2007;26(11):1163-9,
http://dx.doi.org/10.1016/j.healun.2007.07.042.
http://dx.doi.org/10.1016/j.healun.2007....
). Antibody-depleting strategies using plasma
exchange, double filtration plasmapheresis, intravenous immunoglobulin (IVIg), rituximab and, more
recently, the plasma cell-depleting agent bortezomib have produced variable results in children
(88. Asante-Korang A, Jacobs JP, Ringewald J, Carapellucci J, Rosenberg K, McKenna D,
et al. Management of children undergoing cardiac transplantation with high Panel Reactive
Antibodies. Cardiol Young. 2011;21 Suppl 2:124-32,
http://dx.doi.org/10.1017/S1047951111001703.
http://dx.doi.org/10.1017/S1047951111001...
,1111. Reinsmoen NL, Lai CH, Vo A, Jordan SC. Evolving paradigms for desensitization in
managing broadly HLA sensitized transplant candidates. Discov Med.
2012;13(71):267-73.). However, this
sensitized group is growing because of the increase in patients requiring re-transplantation who are
sensitized to their failed allografts.
Mortality is highest immediately after transplantation, particularly in to technically difficult
patients (1212. Aurora P, Edwards LB, Kucheryavaya AY, Christie JD, Dobbels F, Kirk R, et al.
The Registry of the International Society for Heart and Lung Transplantation: thirteenth official
pediatric lung and heart-lung transplantation report-2010. J Heart Lung Transplant.
2010;29(10):1129-41, http://dx.doi.org/10.1016/j.healun.2010.08.008.
http://dx.doi.org/10.1016/j.healun.2010....
,1313. Kirk R, Edwards LB, Kucheryavaya AY, Benden C, Christie JD, Dobbels F, et al.
The Registry of the International Society for Heart and Lung Transplantation: Fourteenth Pediatric
Heart Transplantation Report-2011. J Heart Lung Transplant. 2011;30(10):1095-103,
http://dx.doi.org/10.1016/j.healun.2011.08.005.
http://dx.doi.org/10.1016/j.healun.2011....
). If
patients survive beyond this period, late mortality is low and is more often associated with the
side effects of immunosuppression. In fact, conditional survival for infant heart transplants who
survived the first transplant year approaches 20 years [19.2 years for those transplanted
between the ages of 1-10 years and 15.9 years for older children (1313. Kirk R, Edwards LB, Kucheryavaya AY, Benden C, Christie JD, Dobbels F, et al.
The Registry of the International Society for Heart and Lung Transplantation: Fourteenth Pediatric
Heart Transplantation Report-2011. J Heart Lung Transplant. 2011;30(10):1095-103,
http://dx.doi.org/10.1016/j.healun.2011.08.005.
http://dx.doi.org/10.1016/j.healun.2011....
)]. The causes of mortality therefore evolve after transplantation, with the major
late causes of mortality including sepsis, cardiovascular causes and post-transplant
lymphoproliferative disorder (PTLD) (1414. Foster BJ, Dahhou M, Zhang X, Platt RW, Hanley JA. Change in mortality risk over
time in young kidney transplant recipients. Am J Transplant.
2011;11(11):2432-42.). Chronic allograft
dysfunction leading to loss of the allograft is also an important cause of mortality and will be
discussed subsequently. Infections have overtaken rates of rejection as the major cause of hospital
admission (1313. Kirk R, Edwards LB, Kucheryavaya AY, Benden C, Christie JD, Dobbels F, et al.
The Registry of the International Society for Heart and Lung Transplantation: Fourteenth Pediatric
Heart Transplantation Report-2011. J Heart Lung Transplant. 2011;30(10):1095-103,
http://dx.doi.org/10.1016/j.healun.2011.08.005.
http://dx.doi.org/10.1016/j.healun.2011....
).
The rate of PTLD is highest in the first few years after transplantation, which is related to
higher doses of immunosuppression, although the risks still persist longer than a few years. The
risk of developing PTLD is <5% after renal, liver and heart transplantation (1515. Ng VL, Alonso EM, Bucuvalas JC, Cohen G, Limbers CA, Varni JW, et al. Health
status of children alive 10 years after pediatric liver transplantation performed in the US and
Canada: report of the studies of pediatric liver transplantation experience. J Pediatr.
2012;160(5):820-6 e3, http://dx.doi.org/10.1016/j.jpeds.2011.10.038.
http://dx.doi.org/10.1016/j.jpeds.2011.1...
,1616. Webber SA, Naftel DC, Fricker FJ, Olesnevich P, Blume ED, Addonizio L, et al.
Lymphoproliferative disorders after paediatric heart transplantation: a multi-institutional study.
Lancet. 2006;367(9506):233-9, http://dx.doi.org/10.1016/S0140-6736(06)67933-6.
http://dx.doi.org/10.1016/S0140-6736(06)...
) and <10% after
lung and intestinal transplantation. Pediatric patients are at a higher risk of developing PTLD
because more of them are EBV-naïve. Therefore, routine monitoring for EBV viremia in these
patients allows immunosuppression to be adjusted but does not predict which patients will develop
PTLD (1717. Hocker B, Fickenscher H, Delecluse HJ, Bohm S, Kusters U, Schnitzler P, et al.
Epidemiology and morbidity of Epstein-Barr virus infection in pediatric renal transplant recipients:
a multicenter, prospective study. Clin Infect Dis. 2013;56(1):84-92,
http://dx.doi.org/10.1093/cid/cis823.
http://dx.doi.org/10.1093/cid/cis823...
). SOT recipients are also at risk for other types of
cancers, particularly skin cancer, genitourinary cancer, Kaposi sarcoma and papillary thyroid
cancer.
Allograft survival
Although allograft survival in the immediate post-operative period has improved substantially,
there have been no significant improvements in longer-term allograft survival. Figure 1 presents the renal allograft survival rates after living donor
transplantation by era in North America, which are also representative of the rates for other
transplant recipients worldwide (11. North American Pediatric Renal Trials and Collaborative Studies. 2011 Annual
Transplant Report. [30 October 2013]; Available from:
https://web.emmes.com/study/ped/annlrept/annualrept2011.pdf.
https://web.emmes.com/study/ped/annlrept...
). There is no longer a
sharp decline in allograft survival early after transplantation, but the slope of allograft survival
has not changed between transplant eras. The change in early survival can partly be explained by
better control of early acute allograft rejection. Acute renal allograft rejection in the first year
after transplantation has decreased from 54% pre-1990 to 8.6% in 2010 (11. North American Pediatric Renal Trials and Collaborative Studies. 2011 Annual
Transplant Report. [30 October 2013]; Available from:
https://web.emmes.com/study/ped/annlrept/annualrept2011.pdf.
https://web.emmes.com/study/ped/annlrept...
). Acute cardiac allograft rejection in the first year after transplantation has
decreased from 60% to 40% in the last decade (1818. Gossett JG, Canter CE, Zheng J, Schechtman K, Blume ED, Rodgers S, et al.
Decline in rejection in the first year after pediatric cardiac transplantation: a
multi-institutional study. The Journal of heart and lung transplantation. J Heart Lung
Transplant. 2010;29(6):625-32, http://dx.doi.org/10.1016/j.healun.2009.12.009.
http://dx.doi.org/10.1016/j.healun.2009....
).
Renal allograft survival after living donor transplantation by era. Taken from the NAPRTCS 2011 Annual Report (11. North American Pediatric Renal Trials and Collaborative Studies. 2011 Annual Transplant Report. [30 October 2013]; Available from: https://web.emmes.com/study/ped/annlrept/annualrept2011.pdf.
https://web.emmes.com/study/ped/annlrept... ).
In the long term, chronic allograft dysfunction is caused by both immune and non-immune causes. Infections play an important role in patient morbidity and also lead to graft decline. Children with congenital abnormalities of the kidney and urinary tract with bladder dysfunction are prone to repeated urinary tract infections, and this is exacerbated by immunosuppression after transplantation. The polyomavirus, BK virus, is renotrophic and can cause tubulo-interstitial nephritis. In lung transplant recipients, early phase respiratory viral infections are linked to worsened allograft outcomes, and CMV has been implicated in bronchiolitis obliterans.
Chronic antibody-mediated rejection (AMR) has been postulated to be one of the main reasons for
the slow invariable progression to allograft loss (1919. Loupy A, Hill GS, Jordan SC. The impact of donor-specific anti-HLA antibodies on
late kidney allograft failure. Nat Rev Nephrol. 2012;8(6):348-57,
http://dx.doi.org/10.1038/nrneph.2012.81.
http://dx.doi.org/10.1038/nrneph.2012.81...
,2020. Kfoury AG, Snow GL, Budge D, Alharethi RA, Stehlik J, Everitt MD, et al. A
longitudinal study of the course of asymptomatic antibody-mediated rejection in heart
transplantation. J Heart Lung Transplant. 2012;31(1):46-51,
http://dx.doi.org/10.1016/j.healun.2011.10.009.
http://dx.doi.org/10.1016/j.healun.2011....
). Chronic AMR has been associated with the de
novo development of post-transplant donor-specific antibodies (DSA) (2121. Ho EK, Vlad G, Vasilescu ER, de la Torre L, Colovai AI, Burke E, et al. Pre- and
posttransplantation allosensitization in heart allograft recipients: major impact of de novo
alloantibody production on allograft survival. Hum Immunol. 2011;72(1):5-10,
http://dx.doi.org/10.1016/j.humimm.2010.10.013.
http://dx.doi.org/10.1016/j.humimm.2010....
). These antibodies are produced by B-cells that have developed high-affinity
receptors targeting HLA mismatches arising from the graft and have undergone class switching from
IgM to IgG with subsequent maturation to plasma cells and memory B-cells (2222. Zarkhin V, Kambham N, Li L, Kwok S, Hsieh SC, Salvatierra O, et al.
Characterization of intra-graft B cells during renal allograft rejection. Kidney Int.
2008;74(5):664-73, http://dx.doi.org/10.1038/ki.2008.249.
http://dx.doi.org/10.1038/ki.2008.249...
,2323. Tsai EW, Wallace WD, Gjertson DW, Reed EF, Ettenger RB. Significance of
intragraft CD138+ lymphocytes and p-S6RP in pediatric kidney transplant biopsies.
Transplantation. 2010;90(8):875-81, http://dx.doi.org/10.1097/TP.0b013e3181f24e3c.
http://dx.doi.org/10.1097/TP.0b013e3181f...
). Memory B-cells and memory T-cells
are difficult to address using current immunosuppressive therapy. One option is to use rituximab, a
B-cell depleting agent, and IVIg, which promotes antibody immunomodulation, to treat active disease
and to increase baseline suppression with the addition of mycophenolate mofetil (MMF), which has
B-cell anti-proliferative effects (2424. Billing H, Rieger S, Ovens J, Susal C, Melk A, Waldherr R, et al. Successful
treatment of chronic antibody-mediated rejection with IVIG and rituximab in pediatric renal
transplant recipients. Transplantation. 2008;86(9):1214-21,
http://dx.doi.org/10.1097/TP.0b013e3181880b35.
http://dx.doi.org/10.1097/TP.0b013e31818...
). The reasons why some
patients develop DSA are not known, but one clear factor is non-compliance with immunosuppressive
medications. In addition, DSA levels can fluctuate in pediatric patients and do not always lead to
chronic allograft dysfunction (2525. Miettinen J, Peräsaari J, Lauronen J, Qvist E, Valta H, Pakarinen M, et al.
Donor-specific HLA antibodies and graft function in children after renal transplantation. Pediatr
Nephrol. 2012;27(6):1011-9, http://dx.doi.org/10.1007/s00467-012-2101-4.
http://dx.doi.org/10.1007/s00467-012-210...
). This is an area under
intense investigation, and future techniques may involve immunoglobulin profiling and
complement-fixing HLA antibodies (2626. Honger G, Hopfer H, Arnold ML, Spriewald BM, Schaub S, Amico P. Pretransplant
IgG subclasses of donor-specific human leukocyte antigen antibodies and development of
antibody-mediated rejection. Transplantation. 2011;92(1):41-7,
http://dx.doi.org/10.1097/TP.0b013e31821cdf0d.
http://dx.doi.org/10.1097/TP.0b013e31821...
,2727. Sutherland SM, Chen G, Sequeira FA, Lou CD, Alexander SR, Tyan DB.
Complement-fixing donor-specific antibodies identified by a novel C1q assay are associated with
allograft loss. Pediatr Transplant. 2012;16(1):12-7,
http://dx.doi.org/10.1111/j.1399-3046.2011.01599.x.
http://dx.doi.org/10.1111/j.1399-3046.20...
).
AMR is characterized by microvascular injury on allograft biopsy staining and is associated with
complement activation detected by C4d staining. In the IHSLT registry, AMR of pathological Grade 2
or higher was present in 18% of protocol endomyocardial biopsies, representing 59% of patients
(2828. Everitt MD, Hammond ME, Snow GL, Stehlik J, Revelo MP, Miller DV, et al.
Biopsy-diagnosed antibody-mediated rejection based on the proposed International Society for Heart
and Lung Transplantation working formulation is associated with adverse cardiovascular outcomes
after pediatric heart transplant. J Heart Lung Transplant.2012;31(7):686-93,
http://dx.doi.org/10.1016/j.healun.2012.03.009.
http://dx.doi.org/10.1016/j.healun.2012....
). Patients with Grade 3 AMR had more cardiac allograft
vasculopathy and increased cardiovascular mortality. The role of AMR in liver transplantation is
currently under investigation. C4d staining is present not only in AMR but also in recurrent liver
disease and hepatic necrosis (2929. Ali S, Ormsby A, Shah V, Segovia MC, Kantz KL, Skorupski S, et al. Significance
of complement split product C4d in ABO-compatible liver allograft: diagnosing utility in acute
antibody mediated rejection. Transpl Immunol. 2012;26(1):62-9,
http://dx.doi.org/10.1016/j.trim.2011.08.005.
http://dx.doi.org/10.1016/j.trim.2011.08...
). However, C4d staining in
the presence of DSA often co-exists with cellular rejection and can be steroid-resistant (3030. Musat AI, Agni RM, Wai PY, Pirsch JD, Lorentzen DF, Powell A, et al. The
significance of donor-specific HLA antibodies in rejection and ductopenia development in ABO
compatible liver transplantation. Am J Transplant. 2011;11(3):500-10.).
Current immunosuppression strategies usually consist of a calcineurin inhibitor (CNI) and an
anti-proliferative agent in addition to corticosteroids, with variable use of monoclonal antibodies
at induction (11. North American Pediatric Renal Trials and Collaborative Studies. 2011 Annual
Transplant Report. [30 October 2013]; Available from:
https://web.emmes.com/study/ped/annlrept/annualrept2011.pdf.
https://web.emmes.com/study/ped/annlrept...
,1212. Aurora P, Edwards LB, Kucheryavaya AY, Christie JD, Dobbels F, Kirk R, et al.
The Registry of the International Society for Heart and Lung Transplantation: thirteenth official
pediatric lung and heart-lung transplantation report-2010. J Heart Lung Transplant.
2010;29(10):1129-41, http://dx.doi.org/10.1016/j.healun.2010.08.008.
http://dx.doi.org/10.1016/j.healun.2010....
,1313. Kirk R, Edwards LB, Kucheryavaya AY, Benden C, Christie JD, Dobbels F, et al.
The Registry of the International Society for Heart and Lung Transplantation: Fourteenth Pediatric
Heart Transplantation Report-2011. J Heart Lung Transplant. 2011;30(10):1095-103,
http://dx.doi.org/10.1016/j.healun.2011.08.005.
http://dx.doi.org/10.1016/j.healun.2011....
). Current immunosuppression strategies aim to
balance the prevention of rejection and the side effect profile. Tacrolimus has generally replaced
ciclosporin as the first-line CNI because of its better potency and reduced nephrotoxicity (11. North American Pediatric Renal Trials and Collaborative Studies. 2011 Annual
Transplant Report. [30 October 2013]; Available from:
https://web.emmes.com/study/ped/annlrept/annualrept2011.pdf.
https://web.emmes.com/study/ped/annlrept...
,1212. Aurora P, Edwards LB, Kucheryavaya AY, Christie JD, Dobbels F, Kirk R, et al.
The Registry of the International Society for Heart and Lung Transplantation: thirteenth official
pediatric lung and heart-lung transplantation report-2010. J Heart Lung Transplant.
2010;29(10):1129-41, http://dx.doi.org/10.1016/j.healun.2010.08.008.
http://dx.doi.org/10.1016/j.healun.2010....
,1313. Kirk R, Edwards LB, Kucheryavaya AY, Benden C, Christie JD, Dobbels F, et al.
The Registry of the International Society for Heart and Lung Transplantation: Fourteenth Pediatric
Heart Transplantation Report-2011. J Heart Lung Transplant. 2011;30(10):1095-103,
http://dx.doi.org/10.1016/j.healun.2011.08.005.
http://dx.doi.org/10.1016/j.healun.2011....
,3131. Trompeter R, Filler G, Webb NJ, Watson AR, Milford DV, Tyden G, et al.
Randomized trial of tacrolimus versus cyclosporin microemulsion in renal transplantation. Pediatr.
2002;17(3):141-9.). Basiliximab and daclizumab are
IL2R-alpha monoclonal antibody inhibitors that are effective T-cell activation blockers, but they
have not been demonstrated to improve renal allograft outcomes in pediatric renal transplant
recipients when used in addition to the standard triple therapy of prednisolone, azathioprine and
tacrolimus (3232. Grenda R, Watson A, Vondrak K, Webb NJ, Beattie J, Fitzpatrick M, et al. A
prospective, randomized, multicenter trial of tacrolimus-based therapy with or without basiliximab
in pediatric renal transplantation. Am J Transplant. 2006;6(7):1666-72.). However, the use of IL2R-alpha monoclonal
antibody inhibitors allows rapid weaning of other immunosuppressive agents, such as corticosteroids
(3333. Grenda R, Watson A, Trompeter R, Tonshoff B, Jaray J, Fitzpatrick M, et al. A
randomized trial to assess the impact of early steroid withdrawal on growth in pediatric renal
transplantation: the TWIST study. Am J Transplant. 2010;10(4):828-36.). The use of induction agents has also increased in heart
and lung transplantation but has not been associated with improvements in graft outcomes at 5 years
post-transplant (1212. Aurora P, Edwards LB, Kucheryavaya AY, Christie JD, Dobbels F, Kirk R, et al.
The Registry of the International Society for Heart and Lung Transplantation: thirteenth official
pediatric lung and heart-lung transplantation report-2010. J Heart Lung Transplant.
2010;29(10):1129-41, http://dx.doi.org/10.1016/j.healun.2010.08.008.
http://dx.doi.org/10.1016/j.healun.2010....
,1313. Kirk R, Edwards LB, Kucheryavaya AY, Benden C, Christie JD, Dobbels F, et al.
The Registry of the International Society for Heart and Lung Transplantation: Fourteenth Pediatric
Heart Transplantation Report-2011. J Heart Lung Transplant. 2011;30(10):1095-103,
http://dx.doi.org/10.1016/j.healun.2011.08.005.
http://dx.doi.org/10.1016/j.healun.2011....
). In intestinal transplantation, the use of IL2-blockers has been effective at reducing
acute rejection rates but can be associated with an increased risk of PTLD long after
transplantation (3434. Mazariegos GV, Steffick DE, Horslen S, Farmer D, Fryer J, Grant D, et al.
Intestine transplantation in the United States, 1999-2008. Am J Transplant. 2010;10(4 Pt
2):1020-34.).
Tolerance is defined as stable allograft function in the absence of any immunosuppression. Tolerance can be induced via bone marrow transplantation, as has been described in a case series of multiple myeloma patients who subsequently received renal transplants from the same donor (3535. Fudaba Y, Spitzer TR, Shaffer J, Kawai T, Fehr T, Delmonico F, et al. Myeloma responses and tolerance following combined kidney and nonmyeloablative marrow transplantation: in vivo and in vitro analyses. Am J Transplant. 2006;6(9):2121-33.). However, caution is warranted, as bone marrow transplantation carries a high risk of mortality currently exceeding that of standard solid organ transplants and therefore remains an experimental procedure. Recently, a modified reduced induction regimen with infusion of a facilitating cell population has been described with positive results. Persistent graft chimerism and stable allograft function appear to be present at one-year follow-up, but longer-term results are pending (3636. Leventhal J, Abecassis M, Miller J, Gallon L, Ravindra K, Tollerud DJ, et al. Chimerism and tolerance without GVHD or engraftment syndrome in HLA-mismatched combined kidney and hematopoietic stem cell transplantation. Sci Transl Med. 2012;4(124):124ra28.).
Tolerance has also been reported in patients who have been weaned from immunosuppression either
through non-compliance or secondary to medical reasons. However, these cases remain rare,
particularly in the pediatric literature. Spontaneous tolerance has best been described in liver
transplantation, and currently active trials are aiming at active immunosuppression weaning with
close follow-up (3737. Feng S, Ekong UD, Lobritto SJ, Demetris AJ, Roberts JP, Rosenthal P, et al.
Complete immunosuppression withdrawal and subsequent allograft function among pediatric recipients
of parental living donor liver transplants. JAMA. 2012;307(3):283-93,
http://dx.doi.org/10.1001/jama.2011.2014.
http://dx.doi.org/10.1001/jama.2011.2014...
,3838. Li L, Wozniak LJ, Rodder S, Heish S, Talisetti A, Wang Q, et al. A common
peripheral blood gene set for diagnosis of operational tolerance in pediatric and adult liver
transplantation. Am J Transplant. 2012;12(5):1218-28.). Studies of liver transplant tolerance have reported an increase in NK and NKT cells
(3939. Martinez-Llordella M, Lozano JJ, Puig-Pey I, Orlando G, Tisone G, Lerut J, et
al. Using transcriptional profiling to develop a diagnostic test of operational tolerance in liver
transplant recipients. J Clin Invest. 2008;118(8):2845-57.). In adult renal transplant tolerant patients, two
cross-validated microarray studies have reported an increase in B cell frequency with a concomitant
increase in B cell gene transcript signature (4040. Newell KA, Asare A, Kirk AD, Gisler TD, Bourcier K, Suthanthiran M, et al.
Identification of a B cell signature associated with renal transplant tolerance in humans.
J Clin Invest. 2010;120(6):1836-47, http://dx.doi.org/10.1172/JCI39933.
http://dx.doi.org/10.1172/JCI39933...
,4141. Sagoo P, Perucha E, Sawitzki B, Tomiuk S, Stephens DA, Miqueu P, et al.
Development of a cross-platform biomarker signature to detect renal transplant tolerance in humans.
J Clin Invest. 2010;120(6):1848-61, http://dx.doi.org/10.1172/JCI39922.
http://dx.doi.org/10.1172/JCI39922...
). Studies are currently under way to prospectively validate
these gene markers for tolerance.
Tolerance can also be viewed as a continuum rather than a separate state. There have been concerns that tolerance may not be meta-stable and that infections could tip the balance towards rejection. Therefore, a compromise may involve accepting minimal immunosuppression (such as utilizing a single immunosuppressive agent) rather than a complete cessation of all immunosuppression. The challenge is to identify biomarkers of tolerance to enable safe weaning of immunosuppression.
Cardiovascular risk factors
Cardiovascular-related deaths are a major component of mortality. Transplant recipients often
exhibit increased cardiac dysfunction and usually present unexpectedly in extremis. The main causes
of cardiac death include heart failure and arrhythmias (4242. Filler G. Challenges in pediatric transplantation: the impact of chronic kidney
disease and cardiovascular risk factors on long-term outcomes and recommended management strategies.
Pediatr Transplant. 2011;15(1):25-31,
http://dx.doi.org/10.1111/j.1399-3046.2010.01439.x.
http://dx.doi.org/10.1111/j.1399-3046.20...
),
in contrast with the general population, in which the major cause is progressive ischemic heart
disease. There are also differences in cardiac lesions, as transplant recipients tend to exhibit
global arteriosclerotic calcification in the intima and media, in contrast to the atherosclerotic
lipid plaques found in elderly patients. However, transplantation itself can improve cardiac
outcomes (1414. Foster BJ, Dahhou M, Zhang X, Platt RW, Hanley JA. Change in mortality risk over
time in young kidney transplant recipients. Am J Transplant.
2011;11(11):2432-42.). For example, renal transplant recipients
exhibit improvements in cardiac hypertrophy and reductions in diastolic dysfunction after
transplantation, although not in all cases and often not back to the normal condition (4343. Bullington N, Kartel J, Khoury P, Mitsnefes M. Left ventricular hypertrophy in
pediatric kidney transplant recipients: long-term follow-up study. Pediatr Transplant.
2006;10(7):811-5, http://dx.doi.org/10.1111/j.1399-3046.2006.00565.x.
http://dx.doi.org/10.1111/j.1399-3046.20...
44. Kim GB, Kwon BS, Kang HG, Ha JW, Ha IS, Noh CI, et al. Cardiac dysfunction after
renal transplantation; incomplete resolution in pediatric population. Transplantation.
2009;87(11):1737-43, http://dx.doi.org/10.1097/TP.0b013e3181a63f2f.
http://dx.doi.org/10.1097/TP.0b013e3181a...
-4545. Mitsnefes MM, Kimball TR, Border WL, Witt SA, Glascock BJ, Khoury PR, et al.
Abnormal cardiac function in children after renal transplantation. Am J Kidney Dis.
2004;43(4):721-6.).
Cardiovascular risk factors after transplantation are interlinked and are increased as side
effects of immunosuppression. Hypertension is common, as it is described in 50-75% of renal
transplant recipients, and is associated with left ventricular hypertrophy (4646. Basiratnia M, Esteghamati M, Ajami GH, Amoozgar H, Cheriki C, Soltani M, et al.
Blood pressure profile in renal transplant recipients and its relation to diastolic function: tissue
Doppler echocardiographic study. Pediatr Nephrol. 2011;26(3):449-57,
http://dx.doi.org/10.1007/s00467-010-1724-6.
http://dx.doi.org/10.1007/s00467-010-172...
,4747. Mitsnefes MM, Schwartz SM, Daniels SR, Kimball TR, Khoury P, Strife CF. Changes
in left ventricular mass index in children and adolescents after renal transplantation. Pediatr
Transplant. 2001;5(4):279-84,
http://dx.doi.org/10.1034/j.1399-3046.2001.005004279.x.
http://dx.doi.org/10.1034/j.1399-3046.20...
). The prevalence of hypertension in
liver transplant patients is reported to be 15-30% (4848. Bayrakci US, Baskin E, Ozcay F, Gulleroglu K, Ozbay F, Sevmis S, et al. Abnormal
circadian blood pressure regulation in liver transplanted children. Pediatr Transplant.
2012;16(2):160-4, http://dx.doi.org/10.1111/j.1399-3046.2012.01646.x.
http://dx.doi.org/10.1111/j.1399-3046.20...
,4949. McLin VA, Anand R, Daniels SR, Yin W, Alonso EM. Blood pressure elevation in
long-term survivors of pediatric liver transplantation. Am J Transplant.
2012;12(1):183-90.). Transplant recipients require 24-hour ambulatory blood
pressure monitoring to unmask nocturnal hypertension (4646. Basiratnia M, Esteghamati M, Ajami GH, Amoozgar H, Cheriki C, Soltani M, et al.
Blood pressure profile in renal transplant recipients and its relation to diastolic function: tissue
Doppler echocardiographic study. Pediatr Nephrol. 2011;26(3):449-57,
http://dx.doi.org/10.1007/s00467-010-1724-6.
http://dx.doi.org/10.1007/s00467-010-172...
,4949. McLin VA, Anand R, Daniels SR, Yin W, Alonso EM. Blood pressure elevation in
long-term survivors of pediatric liver transplantation. Am J Transplant.
2012;12(1):183-90.,5050. McGlothan KR, Wyatt RJ, Ault BH, Hastings MC, Rogers T, DiSessa T, et al.
Predominance of nocturnal hypertension in pediatric renal allograft recipients. Pediatr Transplant.
2006;10(5):558-64, http://dx.doi.org/10.1111/j.1399-3046.2006.00521.x.
http://dx.doi.org/10.1111/j.1399-3046.20...
).
Hypertension is a side effect of corticosteroids and CNI, which also increases the risk of metabolic
syndrome [obesity, dyslipidemia and diabetes mellitus (5151. Wilson AC, Greenbaum LA, Barletta GM, Chand D, Lin JJ, Patel HP, et al. High
prevalence of the metabolic syndrome and associated left ventricular hypertrophy in pediatric renal
transplant recipients. Pediatr Transplant. 2010;14(1):52-60,
http://dx.doi.org/10.1111/j.1399-3046.2009.01141.x.
http://dx.doi.org/10.1111/j.1399-3046.20...
,5252. Goldsmith D, Pietrangeli CE. The metabolic syndrome following kidney
transplantation. Kidney Int Suppl. 2010(118):S8-14,
http://dx.doi.org/10.1038/ki.2010.210.
http://dx.doi.org/10.1038/ki.2010.210...
)]. Corticosteroids increase the risk of
developing new-onset diabetes after transplantation (NODAT) by increasing peripheral insulin
resistance, and CNI has a direct toxic effect on insulin-producing beta-islet cells in the pancreas.
Registry studies have reported a prevalence of CNI of 1.8-2%, 3% and 3-7% in cardiac, liver and
renal transplant recipients, respectively, and CNI is closely associated with the level and type of
immunosuppression (5353. Burroughs TE, Swindle JP, Salvalaggio PR, Lentine KL, Takemoto SK, Bunnapradist
S, et al. Increasing incidence of new-onset diabetes after transplant among pediatric renal
transplant patients. Transplantation. 2009;88(3):367-73,
http://dx.doi.org/10.1097/TP.0b013e3181ae67f0.
http://dx.doi.org/10.1097/TP.0b013e3181a...
54. Simmonds J, Dewar C, Dawkins H, Burch M, Fenton M. Tacrolimus in pediatric heart
transplantation: ameliorated side effects in the steroid-free, statin era. Clin Transplant.
2009;23(3):415-9, http://dx.doi.org/10.1111/j.1399-0012.2008.00934.x.
http://dx.doi.org/10.1111/j.1399-0012.20...
-5555. Hathout E, Alonso E, Anand R, Martz K, Imseis E, Johnston J, et al.
Post-transplant diabetes mellitus in pediatric liver transplantation. Pediatr Transplant.
2009;13(5):599-605, http://dx.doi.org/10.1111/j.1399-3046.2007.00603.x.
http://dx.doi.org/10.1111/j.1399-3046.20...
). In particular, although it provides a lower rejection rate, tacrolimus also results in
an increased risk of NODAT compared with ciclosporin (3131. Trompeter R, Filler G, Webb NJ, Watson AR, Milford DV, Tyden G, et al.
Randomized trial of tacrolimus versus cyclosporin microemulsion in renal transplantation. Pediatr.
2002;17(3):141-9.,5656. Filler G, Webb NJ, Milford DV, Watson AR, Gellermann J, Tyden G, et al.
Four-year data after pediatric renal transplantation: a randomized trial of tacrolimus vs.
cyclosporin microemulsion. Pediatr Transplant. 2005;9(4):498-503,
http://dx.doi.org/10.1111/j.1399-3046.2005.00334.x.
http://dx.doi.org/10.1111/j.1399-3046.20...
). In one study, tacrolimus had an odds ratio of
9.1 for development of NODAT compared with ciclosporin (5757. Greenspan LC, Gitelman SE, Leung MA, Glidden DV, Mathias RS. Increased incidence
in post-transplant diabetes mellitus in children: a case-control analysis. Pediatric Nephrol.
2002;17(1):1-5, http://dx.doi.org/10.1007/s004670200000.
http://dx.doi.org/10.1007/s004670200000...
).
In renal transplantation, two different strategies have been investigated, namely corticosteroid
withdrawal and CNI minimization, which are discussed below. Obesity is an increasing healthcare
problem that has clear cardiovascular consequences. The prevalence of obesity has also risen in
pediatric renal transplant recipients from 8% before 1985 to 12.5% after 1985, with a more recent
study estimating the prevalence of diabetes to be as high as 30% (5858. Hanevold CD, Ho PL, Talley L, Mitsnefes MM. Obesity and renal transplant
outcome: A report of the North American Pediatric Renal Transplant Cooperative Study. Pediatrics.
2005;115(2):352-6, http://dx.doi.org/10.1542/peds.2004-0289.
http://dx.doi.org/10.1542/peds.2004-0289...
,5959. Denburg MR, Pradhan M, Shults J, Jones A, Palmer JA, Baluarte HJ, et al.
Longitudinal relations between obesity and hypertension following pediatric renal transplantation.
Pediatric Nephrol. 2010;25(10):2129-39,
http://dx.doi.org/10.1007/s00467-010-1572-4.
http://dx.doi.org/10.1007/s00467-010-157...
). Obesity is associated with a higher risk of
death from cardiopulmonary causes (adjusted relative risks of 3.65 for living donors and 2.94 for
deceased donors) and higher rates of allograft loss (19% vs. 10%) in transplanted
children. In liver transplantation, the risk is 14-16% and remains high long after transplantation
(1515. Ng VL, Alonso EM, Bucuvalas JC, Cohen G, Limbers CA, Varni JW, et al. Health
status of children alive 10 years after pediatric liver transplantation performed in the US and
Canada: report of the studies of pediatric liver transplantation experience. J Pediatr.
2012;160(5):820-6 e3, http://dx.doi.org/10.1016/j.jpeds.2011.10.038.
http://dx.doi.org/10.1016/j.jpeds.2011.1...
,6060. Perito ER, Glidden D, Roberts JP, Rosenthal P. Overweight and obesity in
pediatric liver transplant recipients: prevalence and predictors before and after transplant, United
Network for Organ Sharing Data, 1987-2010. Pediatr Transplant. 2012;16(1):41-9,
http://dx.doi.org/10.1111/j.1399-3046.2011.01598.x.
http://dx.doi.org/10.1111/j.1399-3046.20...
). Obesity
following cardiac transplantation occurs less frequently and is estimated at 8%, possibly because of
the focus of corticosteroid withdrawal and the use of statins (6161. Kaufman BD, Chuai S, Dobbels F, Shaddy RE. Wasting or obesity at time of
transplant does not predict pediatric heart transplant outcomes: analysis of ISHLT pediatric heart
transplant registry. J Heart Lung Transplant. 2009;28(12):1273-8,
http://dx.doi.org/10.1016/j.healun.2009.07.020.
http://dx.doi.org/10.1016/j.healun.2009....
). The use of statins in other solid organ transplant recipients requires further
investigation (6262. Riella LV, Gabardi S, Chandraker A. Dyslipidemia and its therapeutic challenges
in renal transplantation. Am J Transplant. 2012;12(8):1975-82.).
Renal dysfunction
Renal dysfunction is an important cause of morbidity after transplantation. In severe cases, renal dysfunction can lead to end-stage kidney disease requiring dialysis and/or transplantation, but even in mild to moderate cases, renal dysfunction can cause bone mineral disease, vascular calcification and cardiomyopathy. The prevailing risk factors common to solid organ transplant recipients include renal dysfunction at the time of transplantation and the use of CNI. Renal decline is often an insidious process and requires long-term routine monitoring. Follow-up studies of renal function after transplantation are not comparable because of differences in GFR estimations or measurements and different definitions of CKD. One future option for standardization is to use the definitions set by KDIGO.
The prevalence of renal dysfunction in liver recipients was found to be 17.6% (GFR <90
mL/min/1.73 m2) at a mean of 5.2 years post-transplantation based on SPLIT data (6363. Campbell K, Ng V, Martin S, Magee J, Goebel J, Anand R, et al. Glomerular
filtration rate following pediatric liver transplantation-the SPLIT experience.
Am J Transplant. 2010;10(12):2673-82.). However, the prevalence of CKD was higher in two other studies
(25% and 32%) examining longer-term data closer to ten years after transplantation despite their use
of a lower GFR cut-off (60 and 70 mL/min/1.73 m2, respectively (6363. Campbell K, Ng V, Martin S, Magee J, Goebel J, Anand R, et al. Glomerular
filtration rate following pediatric liver transplantation-the SPLIT experience.
Am J Transplant. 2010;10(12):2673-82.,6464. Harambat J, Ranchin B, Dubourg L, Liutkus A, Hadj-Haissa A, Rivet C, et al.
Renal function in pediatric liver transplantation: a long-term follow-up study. Transplantation.
2008;86(8):1028-34, http://dx.doi.org/10.1097/TP.0b013e318187748f.
http://dx.doi.org/10.1097/TP.0b013e31818...
). In cardiac transplant patients, the
rate of freedom from late renal dysfunction (GFR <60 mL/min/1.73 m2) was 71% and 57%
at five and ten years (6565. Feingold B, Zheng J, Law YM, Morrow WR, Hoffman TM, Schechtman KB, et al. Risk
factors for late renal dysfunction after pediatric heart transplantation: a multi-institutional
study. Pediatr Transplant. 2011;15(7):699-705,
http://dx.doi.org/10.1111/j.1399-3046.2011.01564.x.
http://dx.doi.org/10.1111/j.1399-3046.20...
). The prevalence of more severe
renal dysfunction, defined as the requirement for dialysis and transplantation or as a plasma
creatinine level above 221 µmol/L, was 11% at 10 years post-transplantation (6666. Kirk R, Edwards LB, Aurora P, Taylor DO, Christie JD, Dobbels F, et al. Registry
of the International Society for Heart and Lung Transplantation: Twelfth Official Pediatric Heart
Transplantation Report-2009. J Heart Lung Transplant. 2009;28(10):993-1006,
http://dx.doi.org/10.1016/j.healun.2009.08.008.
http://dx.doi.org/10.1016/j.healun.2009....
). In lung transplant recipients, renal dysfunction was estimated
to be 10% at 1 year, 23% at 5 years and 35% at 7 years post-transplantation (6767. Aurora P, Edwards LB, Christie JD, Dobbels F, Kirk R, Rahmel AO, et al. Registry
of the International Society for Heart and Lung Transplantation: Twelfth Official Pediatric Lung and
Heart/Lung Transplantation Report-2009. J Heart Lung Transplant. 2009;28(10):1023-30,
http://dx.doi.org/10.1016/j.healun.2009.08.002.
http://dx.doi.org/10.1016/j.healun.2009....
); 21% of intestinal transplant patients were found to exhibit stage IV or V
chronic kidney disease with GFR <29 mL/min/1.73 m2 after five years (6868. Ojo AO, Held PJ, Port FK, Wolfe RA, Leichtman AB, Young EW, et al. Chronic renal
failure after transplantation of a nonrenal organ. N Engl J Med.
2003;349(10):931-40.).
An important cause of nephrotoxicity is CNI usage with ciclosporin and tacrolimus, which can
cause glomerular vascular constriction and shrinkage and in the long term can result in interstitial
fibrosis and arterial hyalinosis. However, patients exhibit variability in the nephrotoxic effects
of CNI because of genetic polymorphisms in the enzymes involved in CNI metabolism, particularly MDR1
and CYP3A, and may suffer renal damage despite being within the target drug range (6969. Grenda R, Prokurat S, Ciechanowicz A, Piatosa B, Kalicinski P. Evaluation of the
genetic background of standard-immunosuppressant-related toxicity in a cohort of 200 paediatric
renal allograft recipients-a retrospective study. Ann Transplant. 2009;14(3):18-24.). Of the two CNIs, tacrolimus is associated with less
nephrotoxicity. Tacrolimus is associated with better GFRs and lower rejection rates than ciclosporin
in pediatric renal transplant recipients (3131. Trompeter R, Filler G, Webb NJ, Watson AR, Milford DV, Tyden G, et al.
Randomized trial of tacrolimus versus cyclosporin microemulsion in renal transplantation. Pediatr.
2002;17(3):141-9.). In patients
with CNI toxicity, one option is CNI minimization or even withdrawal with intensification or
substitution of alternative immunosuppressive agents, such as MMF or sirolimus. The timing of CNI
withdrawal is important, as nephrotoxicity from CNI is not reversible when performed too late, but
the chances of successful withdrawal are improved if undertaken later after transplantation (7070. Groetzner J, Kaczmarek I, Schulz U, Stegemann E, Kaiser K, Wittwer T, et al.
Mycophenolate and sirolimus as calcineurin inhibitor-free immunosuppression improves renal function
better than calcineurin inhibitor-reduction in late cardiac transplant recipients with chronic renal
failure. Transplantation. 2009;87(5):726-33,
http://dx.doi.org/10.1097/TP.0b013e3181963371.
http://dx.doi.org/10.1097/TP.0b013e31819...
,7171. Mourer JS, Hartigh J, van Zwet EW, Mallat MJ, Dubbeld J, de Fijter JW.
Randomized trial comparing late concentration-controlled calcineurin inhibitor or mycophenolate
mofetil withdrawal. Transplantation. 2012;93(9):887-94,
http://dx.doi.org/10.1097/TP.0b013e31824ad60a.
http://dx.doi.org/10.1097/TP.0b013e31824...
). Although CNI
minimization has been shown to be effective in stabilizing renal function decline, it must be
monitored with caution, as there has been evidence of increased rejection rates (7272. Krischock L, Gullett A, Bockenhauer D, Rees L, Trompeter RS, Marks SD.
Calcineurin-inhibitor free immunosuppression with mycophenolate mofetil and corticosteroids in
paediatric renal transplantation improves renal allograft function without increasing acute
rejection. Pediatr Transplant. 2009;13(4):475-81,
http://dx.doi.org/10.1111/j.1399-3046.2008.01031.x.
http://dx.doi.org/10.1111/j.1399-3046.20...
73. Hocker B, Tonshoff B. Calcineurin inhibitor-free immunosuppression in pediatric
renal transplantation: a viable option? Paediatr drugs. 2011;13(1):49-69.
74. Flechner SM, Kobashigawa J, Klintmalm G. Calcineurin inhibitor-sparing regimens
in solid organ transplantation: focus on improving renal function and nephrotoxicity. Clin
Transplant. 2008;22(1):1-15.-7575. Weintraub L, Li L, Kambham N, Alexander S, Concepcion W, Miller K, et al.
Patient selection critical for calcineurin inhibitor withdrawal in pediatric kidney transplantation.
Pediatr Transplant. 2008;12(5):541-9,
http://dx.doi.org/10.1111/j.1399-3046.2007.00847.x.
http://dx.doi.org/10.1111/j.1399-3046.20...
). In addition,
longer-term follow-up studies are needed to ensure that the improvements are maintained,
particularly without an increase in AMR. For patients on MMF, drug monitoring is important to ensure
adequately high therapeutic dosages, which may explain the increase in rejection in other studies
(7676. Hazzan M, Labalette M, Copin MC, Glowacki F, Provot F, Pruv FR, et al.
Predictive factors of acute rejection after early cyclosporine withdrawal in renal transplant
recipients who receive mycophenolate mofetil: results from a prospective, randomized trial.
J Am Soc Nephrol. 2005;16(8):2509-16,
http://dx.doi.org/10.1681/ASN.2005030312.
http://dx.doi.org/10.1681/ASN.2005030312...
,7777. Tonshoff B, David-Neto E, Ettenger R, Filler G, van Gelder T, Goebel J, et al.
Pediatric aspects of therapeutic drug monitoring of mycophenolic acid in renal transplantation.
Transplantation Rev (Orlando). 2011;25(2):78-89,
http://dx.doi.org/10.1016/j.trre.2011.01.001.
http://dx.doi.org/10.1016/j.trre.2011.01...
). Among
patients on the mTOR inhibitors sirolimus and everolimus who exhibit improved renal function, there
is a high incidence of side effects, including aphthous ulcers, dyslipidemia, myeloid suppression
and proteinuria, necessitating the conversion to alternative medications (7878. Hymes LC, Warshaw BL. Five-year experience using sirolimus-based, calcineurin
inhibitor-free immunosuppression in pediatric renal transplantation. Pediatr Transplant.
2011;15(4):437-41, http://dx.doi.org/10.1111/j.1399-3046.2011.01477.x.
http://dx.doi.org/10.1111/j.1399-3046.20...
) and counterfoing the benefit of CNI minimization (7373. Hocker B, Tonshoff B. Calcineurin inhibitor-free immunosuppression in pediatric
renal transplantation: a viable option? Paediatr drugs. 2011;13(1):49-69.,7474. Flechner SM, Kobashigawa J, Klintmalm G. Calcineurin inhibitor-sparing regimens
in solid organ transplantation: focus on improving renal function and nephrotoxicity. Clin
Transplant. 2008;22(1):1-15.,7979. Dell-Olio D, Kelly DA. Calcineurin inhibitor minimization in pediatric liver
allograft recipients. Pediatr Transplant. 2009;13(6):670-81,
http://dx.doi.org/10.1111/j.1399-3046.2009.01184.x.
http://dx.doi.org/10.1111/j.1399-3046.20...
). A new immunosuppressive agent that was recently approved by the FDA is the
co-stimulatory inhibitor belatacept. In the phase 3 trial BENEFIT, adult transplant recipients
prescribed belatacept with CNI avoidance exhibited better GFRs at 3 years post-transplantation
(8080. Vincenti F, Charpentier B, Vanrenterghem Y, Rostaing L, Bresnahan B, Darji P, et
al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal
transplant recipients (BENEFIT study). Am J Transplant.
2010;10(3):535-46.). However, patients who are EBV-naïve are
contra-indicated for this treatment because of the higher rate of PTLD, which would exclude a large
number of pediatric patients from treatment with belatacept.
Growth
Because of their underlying chronic conditions, children with organ failure are usually shorter
than their peers prior to transplantation but exhibit improved growth after transplantation. Growth
is important, as it is linked to better functional outcomes in employment, education and marital
life (8181. Broyer M, Le Bihan C, Charbit M, Guest G, Tete MJ, Gagnadoux MF, et al.
Long-term social outcome of children after kidney transplantation. Transplantation.
2004;77(7):1033-7, http://dx.doi.org/10.1097/01.TP.0000120947.75697.8B.
http://dx.doi.org/10.1097/01.TP.00001209...
,8282. Alonso EM, Shepherd R, Martz KL, Yin W, Anand R. Linear growth patterns in
prepubertal children following liver transplantation. Am J Transplant.
2009;9(6):1389-97.).
NAPRTCS data have demonstrated that catch-up growth is best achieved in children transplanted
younger, especially those below six years of age (Figure 2) (11. North American Pediatric Renal Trials and Collaborative Studies. 2011 Annual
Transplant Report. [30 October 2013]; Available from:
https://web.emmes.com/study/ped/annlrept/annualrept2011.pdf.
https://web.emmes.com/study/ped/annlrept...
). In children who had achieved
final adult height, the mean Z-score was found to be -1.40; however, improvement was observed over
the years, with the most recent cohort exhibiting Z-scores of -0.94 (11. North American Pediatric Renal Trials and Collaborative Studies. 2011 Annual
Transplant Report. [30 October 2013]; Available from:
https://web.emmes.com/study/ped/annlrept/annualrept2011.pdf.
https://web.emmes.com/study/ped/annlrept...
). Pediatric renal transplant recipients treated with daclizumab, mycophenolate mofetil and
a quick corticosteroid wean over 4 days in the TWIST study exhibited a mean SDS change of 0.16
compared with 0.03 in the standard regimen group at 6 months with no increase in rejection rates;
longer-term data are being currently analyzed (3333. Grenda R, Watson A, Trompeter R, Tonshoff B, Jaray J, Fitzpatrick M, et al. A
randomized trial to assess the impact of early steroid withdrawal on growth in pediatric renal
transplantation: the TWIST study. Am J Transplant. 2010;10(4):828-36.). In a more
recent study with 3-year outcomes, growth was also better in the corticosteroid-free regimen in a
subgroup analysis of pediatric renal transplant recipients under 5 years of age (change in SDS
score: -0.43 vs. -1.07). The corticosteroid-free regimen was safe, with similar
allograft survival, and the patients exhibited lower blood pressure and cholesterol levels (8383. Sarwal MM, Ettenger RB, Dharnidharka V, Benfield M, Mathias R, Portale A, et al.
Complete steroid avoidance is effective and safe in children with renal transplants: a multicenter
randomized trial with three-year follow-up. Am J Transplant.
2012;12(10):2719-29.). These results have been reproduced in other studies, which
should prompt consideration of early corticosteroid withdrawal if not complete corticosteroid
avoidance in uncomplicated transplants (8484. Klare B, Montoya CR, Fischer DC, Stangl MJ, Haffner D. Normal adult height after
steroid-withdrawal within 6 months of pediatric kidney transplantation: a 20 years single center
experience. Transpl Int. 2012;25(3):276-82,
http://dx.doi.org/10.1111/j.1432-2277.2011.01400.x.
http://dx.doi.org/10.1111/j.1432-2277.20...
85. Delucchi A, Valenzuela M, Lillo AM, Guerrero JL, Cano F, Azocar M, et al. Early
steroid withdrawal in pediatric renal transplant: five years of follow-up. Pediatric Nephrol.
2011;26(12):2235-44, http://dx.doi.org/10.1007/s00467-011-1934-6.
http://dx.doi.org/10.1007/s00467-011-193...
86. Hocker B, Weber LT, Feneberg R, Drube J, John U, Fehrenbach H, et al. Improved
growth and cardiovascular risk after late steroid withdrawal: 2-year results of a prospective,
randomised trial in paediatric renal transplantation. Nephrol Dial Transplant. 2010;25(2):617-24,
http://dx.doi.org/10.1093/ndt/gfp506.
http://dx.doi.org/10.1093/ndt/gfp506...
-8787. Diem HV, Sokal EM, Janssen M, Otte JB, Reding R. Steroid withdrawal after
pediatric liver transplantation: a long-term follow-up study in 109 recipients. Transplantation.
2003;75(10):1664-70, http://dx.doi.org/10.1097/01.TP.0000063938.49112.C2.
http://dx.doi.org/10.1097/01.TP.00000639...
).
Catch-up growth according to the age at renal transplantation. Taken from the NAPRTCS 2011 Annual Report (11. North American Pediatric Renal Trials and Collaborative Studies. 2011 Annual Transplant Report. [30 October 2013]; Available from: https://web.emmes.com/study/ped/annlrept/annualrept2011.pdf.
https://web.emmes.com/study/ped/annlrept... ).
The use of recombinant human growth hormone remains controversial, especially as it may confer an
increased risk of PTLD. In the most recent Cochrane update, children who were treated with growth
hormone (28 IU/m2/week) exhibited an increased height velocity of 3.88 cm/year (8888. Hodson EM, Willis NS, Craig JC. Growth hormone for children with chronic kidney
disease. Cochrane Database Syst Rev. 2012;2:CD003264.). In one non-randomized study, final height was significantly
higher in patients treated with growth hormone, although the height in the control group was well
below the average (Z-score -1.88 vs. -3.48) (8989. Gil S, Vaiani E, Guercio G, Ciaccio M, Turconi A, Delgado N, et al.
Effectiveness of rhGH treatment on final height of renal-transplant recipients in childhood.
Pediatric Nephrol. 2012;27(6):1005-9, http://dx.doi.org/10.1007/s00467-011-2090-8.
http://dx.doi.org/10.1007/s00467-011-209...
). However, the cost of this treatment is prohibitory in resource-poor countries and has
to be balanced against maximizing nutrition and caloric intake, which can also produce very good
height outcomes (9090. Rees L, Shroff R, Hutchinson C, Fernando ON, Trompeter RS. Long-term outcome of
paediatric renal transplantation: follow-up of 300 children from 1973 to 2000. Nephron Clin Pract.
2007;105(2):c68-76, http://dx.doi.org/10.1159/000097601.
http://dx.doi.org/10.1159/000097601...
). However, some studies did not report
the final adult attained height, and 25(OH) vitamin D deficiency has also been associated with short
stature (9191. Shroff R, Knott C, Gullett A, Wells D, Marks SD, Rees L. Vitamin D deficiency is
associated with short stature and may influence blood pressure control in paediatric renal
transplant recipients. Pediatric Nephrol. 2011;26(12):2227-33,
http://dx.doi.org/10.1007/s00467-011-1920-z.
http://dx.doi.org/10.1007/s00467-011-192...
). It should be noted that puberty is not delayed
in the majority of pediatric transplant recipients, although they invariably exhibit delayed bone
age and achieve final height later (9292. Tainio J, Qvist E, Vehmas R, Jahnukainen K, Holtta T, Valta H, et al. Pubertal
development is normal in adolescents after renal transplantation in childhood. Transplantation.
2011;92(4):404-9, http://dx.doi.org/10.1097/TP.0b013e3182247bd5.
http://dx.doi.org/10.1097/TP.0b013e31822...
).
Liver transplant recipients also exhibit catch-up growth after transplantation. Similar to kidney
transplantation patients, children undergoing liver transplantation in the current era exhibit
better height outcomes (8282. Alonso EM, Shepherd R, Martz KL, Yin W, Anand R. Linear growth patterns in
prepubertal children following liver transplantation. Am J Transplant.
2009;9(6):1389-97.). Improvements in SDS scores are
largest immediately after transplantation, partly because of the normalization of digestive enzymes
and food digestion. In the SPLIT registry, the mean SDS score at 5 years after transplantation was
-0.5 in the most recent cohort (8282. Alonso EM, Shepherd R, Martz KL, Yin W, Anand R. Linear growth patterns in
prepubertal children following liver transplantation. Am J Transplant.
2009;9(6):1389-97.). Growth plateaus 3-5
years after transplantation and, in a study examining 15-year outcomes, height remained static at
-0.47 SDS (9393. El Moghazy WM, Ogura Y, Harada K, Koizumi A, Uemoto S. Can children catch up in
growth after living donor liver transplantation? Liver Transpl. 2010;16(4):453-60.). Improved height gain is associated with less
corticosteroid exposure and non-metabolic conditions (8282. Alonso EM, Shepherd R, Martz KL, Yin W, Anand R. Linear growth patterns in
prepubertal children following liver transplantation. Am J Transplant.
2009;9(6):1389-97.).
Corticosteroid-free and corticosteroid withdrawal regimens have also been used successfully (8787. Diem HV, Sokal EM, Janssen M, Otte JB, Reding R. Steroid withdrawal after
pediatric liver transplantation: a long-term follow-up study in 109 recipients. Transplantation.
2003;75(10):1664-70, http://dx.doi.org/10.1097/01.TP.0000063938.49112.C2.
http://dx.doi.org/10.1097/01.TP.00000639...
,9494. Gras JM, Gerkens S, Beguin C, Janssen M, Smets F, Otte JB, et al. Steroid-free,
tacrolimus-basiliximab immunosuppression in pediatric liver transplantation: clinical and
pharmacoeconomic study in 50 children. Liver Transpl. 2008;14(4):469-77,
http://dx.doi.org/10.1002/lt.21397.
http://dx.doi.org/10.1002/lt.21397...
).
Pediatric cardiac transplant recipients maintain their height SDS score with little catch-up
growth despite improvements in weight (9595. Peterson RE, Perens GS, Alejos JC, Wetzel GT, Chang RK. Growth and weight gain
of prepubertal children after cardiac transplantation. Pediatr Transplant. 2008;12(4):436-41,
http://dx.doi.org/10.1111/j.1399-3046.2007.00826.x.
http://dx.doi.org/10.1111/j.1399-3046.20...
). Lung transplant
recipients tend to be transplanted in their teens and exhibit growth complications associated with
their underlying disease, which is typically cystic fibrosis. Growth after intestinal
transplantation is dependent on the re-establishment of feeding and rejection episodes. Lacaille et
al. managed to achieve normal growth in two-thirds of their series of 31 children (9696. Lacaille F, Vass N, Sauvat F, Canioni D, Colomb V, Talbotec C, et al. Long-term
outcome, growth and digestive function in children 2 to 18 years after intestinal transplantation.
Gut. 2008;57(4):455-61.).
Quality of life
Although life-saving, solid organ transplantation is not curative, and transplanted children continue to exhibit chronic health problems throughout their life. Therefore, transplantation should focus on extending the length of life and also increasing the quality of life. The WHO defines health as a state of complete physical, mental and social well-being and not merely the absence of disease or infirmity. This requires a holistic approach from the multi-disciplinary transplantation team with involvement of primary care physicians, psychologists, social workers and the school, focusing on minimizing attention problems and school absenteeism and maximizing long-lasting relationships with peers and overall school performance.
Quality of life (QoL) can be measured by various indices, which can be general or disease specific. General indices allow comparisons to the general population and across populations but do not address specific issues related to transplantation. Transplant-specific indices are more sensitive to changes in a child's condition and are more useful for measuring longitudinal changes. When possible, QoL questionnaires should be answered by the children themselves. However, there is good agreement between the results reported by children and those reported their parents, although the agreement is higher for observable behaviors than for non-observable emotional and social functions (9797. Eiser C, Morse R. Quality-of-life measures in chronic diseases of childhood. Health Technol Assess. 2001;5(4):1-157.).
Qualitative interview studies are also useful in identifying concerns and highlight generic concerns such as physical health limitations, emotions (including fears and worries about future health, sadness arising from knowledge of their parents worrying about them and self-blame for imposing worry on family members) and school/social concerns (such as poor attendance and bullying).
Pediatric renal transplant recipients exhibit good overall outcomes after transplantation (9898. Karrfelt HM, Berg UB. Long-term psychosocial outcome after renal transplantation
during childhood. Pediatr Transplant. 2008;12(5):557-62,
http://dx.doi.org/10.1111/j.1399-3046.2007.00859.x.
http://dx.doi.org/10.1111/j.1399-3046.20...
,9999. Sundaram SS, Landgraf JM, Neighbors K, Cohn RA, Alonso EM. Adolescent
health-related quality of life following liver and kidney transplantation.
Am J Transplant. 2007;7(4):982-9.). A questionnaire
study of children transplanted before 1999 reported fair or good outcomes in 95% despite a high
prevalence of side effects, and 50% of patients were married and reported satisfaction in their
married lives (8181. Broyer M, Le Bihan C, Charbit M, Guest G, Tete MJ, Gagnadoux MF, et al.
Long-term social outcome of children after kidney transplantation. Transplantation.
2004;77(7):1033-7, http://dx.doi.org/10.1097/01.TP.0000120947.75697.8B.
http://dx.doi.org/10.1097/01.TP.00001209...
,100100. Bartosh SM, Leverson G, Robillard D, Sollinger HW. Long-term outcomes in
pediatric renal transplant recipients who survive into adulthood. Transplantation.
2003;76(8):1195-200, http://dx.doi.org/10.1097/01.TP.0000092524.75807.84.
http://dx.doi.org/10.1097/01.TP.00000925...
). The rate of unemployment approached 27%, which was comparable that in the general
population, and a significant proportion of the patients achieved a university qualification (8181. Broyer M, Le Bihan C, Charbit M, Guest G, Tete MJ, Gagnadoux MF, et al.
Long-term social outcome of children after kidney transplantation. Transplantation.
2004;77(7):1033-7, http://dx.doi.org/10.1097/01.TP.0000120947.75697.8B.
http://dx.doi.org/10.1097/01.TP.00001209...
,9898. Karrfelt HM, Berg UB. Long-term psychosocial outcome after renal transplantation
during childhood. Pediatr Transplant. 2008;12(5):557-62,
http://dx.doi.org/10.1111/j.1399-3046.2007.00859.x.
http://dx.doi.org/10.1111/j.1399-3046.20...
). However, overall QoL
scores were lower than those of healthy peers (101101. Qvist E, Narhi V, Apajasalo M, Ronnholm K, Jalanko H, Almqvist F, et al.
Psychosocial adjustment and quality of life after renal transplantation in early childhood. Pediatr
Transplant. 2004;8(2):120-5, http://dx.doi.org/10.1046/j.1399-3046.2003.00121.x.
http://dx.doi.org/10.1046/j.1399-3046.20...
102. Anthony SJ, Hebert D, Todd L, Korus M, Langlois V, Pool R, et al. Child and
parental perspectives of multidimensional quality of life outcomes after kidney transplantation.
Pediatr Transplant. 2010;14(2):249-56,
http://dx.doi.org/10.1111/j.1399-3046.2009.01214.x.
http://dx.doi.org/10.1111/j.1399-3046.20...
-103103. Falger J, Landolt MA, Latal B, Ruth EM, Neuhaus TJ, Laube GF. Outcome after
renal transplantation. Part II: quality of life and psychosocial adjustment. Pediatric Nephrology.
2008;23(8):1347-54.). The worst outcomes of transplant patients are related to the
side effects of treatment (including body image, obesity, short stature and ulcers) and correlate to
non-adherence, which in turn correlates to allograft function (102102. Anthony SJ, Hebert D, Todd L, Korus M, Langlois V, Pool R, et al. Child and
parental perspectives of multidimensional quality of life outcomes after kidney transplantation.
Pediatr Transplant. 2010;14(2):249-56,
http://dx.doi.org/10.1111/j.1399-3046.2009.01214.x.
http://dx.doi.org/10.1111/j.1399-3046.20...
). Patients also exhibit an increased incidence of somatic complaints and anxiety and
depression (9898. Karrfelt HM, Berg UB. Long-term psychosocial outcome after renal transplantation
during childhood. Pediatr Transplant. 2008;12(5):557-62,
http://dx.doi.org/10.1111/j.1399-3046.2007.00859.x.
http://dx.doi.org/10.1111/j.1399-3046.20...
,104104. Noohi S, Khaghani-Zadeh M, Javadipour M, Assari S, Najafi M, Ebrahiminia M, et
al. Anxiety and depression are correlated with higher morbidity after kidney transplantation.
Transplant Proc. 2007;39(4):1074-8,
http://dx.doi.org/10.1016/j.transproceed.2007.04.002.
http://dx.doi.org/10.1016/j.transproceed...
).
A study utilizing DSM IV criteria reported a 65% risk of lifetime psychiatric disorders in
transplant patients compared with 60% in CKD patients and 37.5% in controls (105105. Berney-Martinet S, Key F, Bell L, Lepine S, Clermont MJ, Fombonne E.
Psychological profile of adolescents with a kidney transplant. Pediatr Transplant.
2009;13(6):701-10, http://dx.doi.org/10.1111/j.1399-3046.2008.01053.x.
http://dx.doi.org/10.1111/j.1399-3046.20...
).
Data from the SPLIT registry, including QoL data, are available for multi-center studies. These
data demonstrate lower physical and psychosocial functioning compared with matched peers but
equivalent functioning to children with other chronic conditions. PedsQL 4.0 Generic Core Scales
were all significantly lower in transplant patients (p<0.001), with effect
sizes ranging from 0.25 for self-reported emotional functioning to 0.68 for self-reported school
functioning (with effect sizes greater than 0.5 considered moderate and 0.8 considered large) (106106. Alonso EM, Limbers CA, Neighbors K, Martz K, Bucuvalas JC, Webb T, et al.
Cross-sectional analysis of health-related quality of life in pediatric liver transplant recipients.
J Pediatr. 2010;156(2):270-6 e1,
http://dx.doi.org/10.1016/j.jpeds.2009.08.048.
http://dx.doi.org/10.1016/j.jpeds.2009.0...
,107107. Alonso EM, Neighbors K, Barton FB, McDiarmid SV, Dunn SP, Mazariegos GV, et al.
Health-related quality of life and family function following pediatric liver transplantation. Liver
Transpl. 2008 Apr;14(4):460-8, http://dx.doi.org/10.1002/lt.21352.
http://dx.doi.org/10.1002/lt.21352...
). Patients
reported better scores than their parents. Time from transplantation did not impact QoL, but length
of stay, number of subsequent days of hospitalization, lower height z-scores, older age and a
history of seizures exerted a negative impact on QoL (106106. Alonso EM, Limbers CA, Neighbors K, Martz K, Bucuvalas JC, Webb T, et al.
Cross-sectional analysis of health-related quality of life in pediatric liver transplant recipients.
J Pediatr. 2010;156(2):270-6 e1,
http://dx.doi.org/10.1016/j.jpeds.2009.08.048.
http://dx.doi.org/10.1016/j.jpeds.2009.0...
,107107. Alonso EM, Neighbors K, Barton FB, McDiarmid SV, Dunn SP, Mazariegos GV, et al.
Health-related quality of life and family function following pediatric liver transplantation. Liver
Transpl. 2008 Apr;14(4):460-8, http://dx.doi.org/10.1002/lt.21352.
http://dx.doi.org/10.1002/lt.21352...
). In summary, transplant patients exhibit
lower QoL compared than the general population but equivalent QoL to other chronic disease
patients.
Heart transplantation leads to dramatic improvements in functional status and allows children to
return to age-appropriate activities, including physical recreational activities and school (108108. Uzark KC, Sauer SN, Lawrence KS, Miller J, Addonizio L, Crowley DC. The
psychosocial impact of pediatric heart transplantation. J Heart Lung Transplant.
1992;11(6):1160-7.,109109. Sigfusson G, Fricker FJ, Bernstein D, Addonizio LJ, Baum D, Hsu DT, et al.
Long-term survivors of pediatric heart transplantation: a multicenter report of sixty-eight children
who have survived longer than five years. J Pediatr. 1997;130(6):862-71,
http://dx.doi.org/10.1016/S0022-3476(97)70270-1.
http://dx.doi.org/10.1016/S0022-3476(97)...
). One qualitative
study found that pediatric cardiac transplantation patients described their lives as ‘mostly
good' or ‘fun' and noted that they valued the normal aspects of life (110110. Green A, McSweeney J, Ainley K, Bryant J. In my shoes: children's quality
of life after heart transplantation. Prog Transplant. 2007 Sep;17(3):199-207; quiz
208.). Another study reported that the majority (78%) of patients
exhibited improved psychological functioning after cardiac transplantation, which was maintained
after a decade. Good physical rehabilitation and lifestyle were typically reported in 10% of
patients transplanted in the early era who survived more than 20 years (111111. Ross M, Kouretas P, Gamberg P, Miller J, Burge M, Reitz B, et al. Ten-and
20-year survivors of pediatric orthotopic heart transplantation. J Heart Lung
Transplant.2006;25(3):261-70, http://dx.doi.org/10.1016/j.healun.2005.09.011.
http://dx.doi.org/10.1016/j.healun.2005....
). However, there is a subset of patients with identifiable psychosocial
problems, including anxiety, depression and behavioral problems (108108. Uzark KC, Sauer SN, Lawrence KS, Miller J, Addonizio L, Crowley DC. The
psychosocial impact of pediatric heart transplantation. J Heart Lung Transplant.
1992;11(6):1160-7.,112112. DeMaso DR, Twente AW, Spratt EG, O'Brien P. Impact of psychologic
functioning, medical severity, and family functioning in pediatric heart transplantation.
J Heart Lung Transplant. 1995;14(6 Pt 1):1102-8.
113. Wray J, Radley-Smith R. Longitudinal assessment of psychological functioning in
children after heart or heart-lung transplantation. J Heart Lung Transplant. 2006;25(3):345-52,
http://dx.doi.org/10.1016/j.healun.2005.09.018.
http://dx.doi.org/10.1016/j.healun.2005....
-114114. Wray J, Radley-Smith R. Beyond the first year after pediatric heart or
heart-lung transplantation: Changes in cognitive function and behaviour. Pediatr Transplant.
2005;9(2):170-7, http://dx.doi.org/10.1111/j.1399-3046.2005.00265.x.
http://dx.doi.org/10.1111/j.1399-3046.20...
).
QoL studies for lung transplant recipients are limited (115115. Lanuza DM, Lefaiver CA, Farcas GA. Research on the quality of life of lung
transplant candidates and recipients: an integrative review. Heart Lung.
2000;29(3):180-95.), although a reduced intensity of psychosocial problems has been suggested (116116. Lanuza DM, Lefaiver C, Mc Cabe M, Farcas GA, Garrity E, Jr. Prospective study
of functional status and quality of life before and after lung transplantation. Chest.
2000;118(1):115-22, http://dx.doi.org/10.1378/chest.118.1.115.
http://dx.doi.org/10.1378/chest.118.1.11...
). In adult QoL studies, general satisfaction with the
transplantation decision and improved QoL scores compared with patients awaiting transplant have
been reported, but significant findings of pain have also been reported (117117. Gross CR, Savik K, Bolman RM, 3rd, Hertz MI. Long-term health status and
quality of life outcomes of lung transplant recipients. Chest. 1995;108(6):1587-93,
http://dx.doi.org/10.1378/chest.108.6.1587.
http://dx.doi.org/10.1378/chest.108.6.15...
,118118. Smeritschnig B, Jaksch P, Kocher A, Seebacher G, Aigner C, Mazhar S, et al.
Quality of life after lung transplantation: a cross-sectional study. J Heart Lung Transplant.
2005;24(4):474-80, http://dx.doi.org/10.1016/j.healun.2003.12.013.
http://dx.doi.org/10.1016/j.healun.2003....
). An important study highlighted
lower QoL scores in caregivers of lung transplant recipients that were correlated with patient
survival rates (119119. Myaskovsky L, Posluszny DM, Schulz R, DiMartini AF, Switzer GE, DeVito Dabbs A,
et al. Predictors and outcomes of health-related quality of life in caregivers of cardiothoracic
transplant recipients. Am J Transplant. 2012;12(12):3387-97.), thus indicating an important avenue of
support to improve transplant outcomes.
In intestinal transplantation, one early study reported similar QoL scores to population controls
in self-reported questionnaires but lower scores in parent assessments (120120. Sudan D, Horslen S, Botha J, Grant W, Torres C, Shaw B, et al. Quality of life
after pediatric intestinal transplantation: the perception of pediatric recipients and their
parents. Am J Transplant. 2004;4(3):407-13.). Therefore, despite the effects of disease on their health, these children
did not report that their daily functioning was affected, which is an important point when
counseling families. This result was reproduced in two recent studies (121121. Ngo KD, Farmer DG, McDiarmid SV, Artavia K, Ament ME, Vargas J, et al.
Pediatric health-related quality of life after intestinal transplantation. Pediatr Transplant.
2011;15(8):849-54, http://dx.doi.org/10.1111/j.1399-3046.2011.01590.x.
http://dx.doi.org/10.1111/j.1399-3046.20...
,122122. Abu-Elmagd KM, Kosmach-Park B, Costa G, Zenati M, Martin L, Koritsky DA, et al.
Long-term survival, nutritional autonomy, and quality of life after intestinal and multivisceral
transplantation. Ann Surg. 2012;256(3):494-508,
http://dx.doi.org/10.1097/SLA.0b013e318265f310.
http://dx.doi.org/10.1097/SLA.0b013e3182...
).
Socioeconomic factors play an important role in the psychosocial support network of children and
their families. Single-parent households, low level of caregiver education and family conflicts are
negative predictors of QoL (106106. Alonso EM, Limbers CA, Neighbors K, Martz K, Bucuvalas JC, Webb T, et al.
Cross-sectional analysis of health-related quality of life in pediatric liver transplant recipients.
J Pediatr. 2010;156(2):270-6 e1,
http://dx.doi.org/10.1016/j.jpeds.2009.08.048.
http://dx.doi.org/10.1016/j.jpeds.2009.0...
,107107. Alonso EM, Neighbors K, Barton FB, McDiarmid SV, Dunn SP, Mazariegos GV, et al.
Health-related quality of life and family function following pediatric liver transplantation. Liver
Transpl. 2008 Apr;14(4):460-8, http://dx.doi.org/10.1002/lt.21352.
http://dx.doi.org/10.1002/lt.21352...
,123123. Taylor RM, Franck LS, Gibson F, Donaldson N, Dhawan A. Study of the factors
affecting health-related quality of life in adolescents after liver transplantation.
Am J Transplant. 2009;9(5):1179-88.). A study evaluating family QoL
scores found that transplantation significantly disrupted daily activities but did not affect family
functioning as assessed by the Family Assessment Device (107107. Alonso EM, Neighbors K, Barton FB, McDiarmid SV, Dunn SP, Mazariegos GV, et al.
Health-related quality of life and family function following pediatric liver transplantation. Liver
Transpl. 2008 Apr;14(4):460-8, http://dx.doi.org/10.1002/lt.21352.
http://dx.doi.org/10.1002/lt.21352...
). The parents of transplant children also suffer symptoms of post-traumatic stress
disorder, with a prevalence of nearly 40% determined using DSM IV criteria in one study (124124. Young GS, Mintzer LL, Seacord D, Castaneda M, Mesrkhani V, Stuber ML. Symptoms
of posttraumatic stress disorder in parents of transplant recipients: incidence, severity, and
related factors. Pediatrics. 2003;111(6 Pt 1):e725-31,
http://dx.doi.org/10.1542/peds.111.6.e725",-1,"xxx/6.e725.
http://dx.doi.org/10.1542/peds.111.6.e72...
,125125. Farley LM, DeMaso DR, D'Angelo E, Kinnamon C, Bastardi H, Hill CE, et al.
Parenting stress and parental post-traumatic stress disorder in families after pediatric heart
transplantation. J Heart Lung Transplant. 2007;26(2):120-6,
http://dx.doi.org/10.1016/j.healun.2006.11.013.
http://dx.doi.org/10.1016/j.healun.2006....
). Psychological
effects on siblings should also be considered in future research. Physicians can minimize family
disruption and potentially improve compliance and outcomes by minimizing hospital visits and
facilitating follow-up assessments and blood tests at local hospital networks.
The cognitive functioning of pediatric transplant recipients needs to be considered in
conjunction with normal brain development. However, cognitive function is determined by the
underlying condition, as some diseases present during infancy at the time of rapid neurodevelopment
and will therefore exhibit a larger impact on cognitive function. Studies generally demonstrate a
lower neurocognitive score in transplant patients compared with the general pediatric population.
One study of pediatric renal transplant recipients reported an FSIQ of 87 (normative mean 100, SD
15) (126126. Qvist E, Pihko H, Fagerudd P, Valanne L, Lamminranta S, Karikoski J, et al.
Neurodevelopmental outcome in high-risk patients after renal transplantation in early childhood.
Pediatr Transplant. 2002;6(1):53-62,
http://dx.doi.org/10.1034/j.1399-3046.2002.1o040.x.
http://dx.doi.org/10.1034/j.1399-3046.20...
). Early renal transplantation has been suggested to
improve cognitive function in infants (127127. Motoyama O, Kawamura T, Aikawa A, Hasegawa A, Iitaka K. Head circumference and
development in young children after renal transplantation. Pediatr Int. 2009;51(1):71-4,
http://dx.doi.org/10.1111/j.1442-200X.2008.02653.x.
http://dx.doi.org/10.1111/j.1442-200X.20...
). In liver
transplantation patients, the FOG/SPLIT group highlighted a high prevalence of cognitive delays and
learning problems, with 26% of patients exhibiting ‘mild to moderate' IQ deficits and
4% exhibiting ‘serious delays' (128128. Sorensen LG, Neighbors K, Martz K, Zelko F, Bucuvalas JC, Alonso EM. Cognitive
and academic outcomes after pediatric liver transplantation: Functional Outcomes Group (FOG)
results. Am J Transplant. 2011;11(2):303-11.). However,
these studies were performed in previous transplant eras. More recent results may be more
encouraging, and longitudinal data are required to determine whether there is any change or
improvement in cognitive function (125125. Farley LM, DeMaso DR, D'Angelo E, Kinnamon C, Bastardi H, Hill CE, et al.
Parenting stress and parental post-traumatic stress disorder in families after pediatric heart
transplantation. J Heart Lung Transplant. 2007;26(2):120-6,
http://dx.doi.org/10.1016/j.healun.2006.11.013.
http://dx.doi.org/10.1016/j.healun.2006....
,129129. Kaller T, Schulz KH, Sander K, Boeck A, Rogiers X, Burdelski M. Cognitive
abilities in children after liver transplantation. Transplantation. 2005;79(9):1252-6,
http://dx.doi.org/10.1097/01.TP.0000161251.20520.42.
http://dx.doi.org/10.1097/01.TP.00001612...
). Children with heart transplants are affected by their period of cyanosis and
any prolonged episodes of brain ischemia resulting from circulatory arrest and cardiopulmonary
bypass. Heart transplantation therefore improves cognitive function, and developmental and academic
assessments have generally been in the normal range (114114. Wray J, Radley-Smith R. Beyond the first year after pediatric heart or
heart-lung transplantation: Changes in cognitive function and behaviour. Pediatr Transplant.
2005;9(2):170-7, http://dx.doi.org/10.1111/j.1399-3046.2005.00265.x.
http://dx.doi.org/10.1111/j.1399-3046.20...
,130130. Chinnock RE, Freier MC, Ashwal S, Pivonka-Jones J, Shankel T, Cutler D, et al.
Developmental outcomes after pediatric heart transplantation. J Heart Lung Transplant.
2008;27(10):1079-84, http://dx.doi.org/10.1016/j.healun.2008.07.012.
http://dx.doi.org/10.1016/j.healun.2008....
).
Transition
Adolescence is a time when allograft recipients can rebel with non-adherence to immunosuppression
and may consequently lose their functioning graft. Therefore, it is important not only to provide
additional support to young adult allograft recipients but also to ensure that they have a smooth
transition to adult physicians, surgeons and multi-disciplinary teams. The ideal transition process
should be individualized according to the needs of the patient and not the requirements of the
services. The patient transition should involve adolescent-trained physicians, surgeons, nurse
specialists, pharmacists and allied health professionals, including the psychosocial team and other
multi-disciplinary team members, such as youth workers. Most transplant centers provide a dedicated
clinic within the adult setting rather than a combined pediatric-adult clinic and have no direct
input or continuity from pediatric services. However, the success of these clinics is dependent on
good communication between the two services, including meetings between the pediatric and adult
clinic staff to plan coordinated care and the involvement of youth workers and transition link
staff, such as nurse specialists (who can escort young people to the adult clinics if required).
However, a better model can be provided in which both pediatric and adult professionals provide
ongoing care in a joint clinic from adolescence through to adulthood, the duration of which can be
individualized (131131. Harden PN, Walsh G, Bandler N, Bradley S, Lonsdale D, Taylor J, et al. Bridging
the gap: an integrated paediatric to adult clinical service for young adults with kidney failure.
BMJ. 2012;344:e3718, http://dx.doi.org/10.1136/bmj.e3718",-1,"xxx/bmj.e3718.
http://dx.doi.org/10.1136/bmj.e3718",-1,...
). Transition programs are set up to
improve patient-related outcome measures and patient experiences. However, improvement of patient
outcomes can only be achieved by careful preparation during the transitioning process, with joint
transition clinics identifying issues and overcoming potential difficulties. Initially, young adults
should have their fears allayed through the allocation of a key liaison member of the staff
assisting in an informal visit to the adult unit during the preparation for transfer. Young adults
may be reluctant to leave friends and healthcare personnel, or they may lack maturity or have
adherence issues and an ongoing dependence on their parents or guardians. The parents may be
reluctant to leave familiar staff and clinic surroundings and may resist attempts by the adult
service to enhance the self-advocacy of the child. Financial or time barriers may also impede
successful transition from the healthcare system. Excellent communication channels are necessary
between pediatric and adult services, with the transfer of documentation (including inpatient and
outpatient medical and nursing notes, operation notes and longitudinal laboratory data, including
histopathology and radiology results and specialist reports). Pediatric medical and nursing staff
may exhibit emotional attachment to patients and lack confidence in the potential care given by
health professionals in the adult clinic because of differences in the attitudes and priorities of
adult services. Adult medical and nursing staff may lack confidence in managing adolescents because
of inadequate training in child and adolescent development or the impact of chronic disease. The
staff may be concerned regarding different dynamics of consultation (such as the presence of parents
in consultations). They may also lack confidence in the pediatric staff if aware of differences in
the attitudes and priorities of pediatric services (such as feeling that the pediatrician has not
managed the patient correctly or has transferred the patient either too early or too late).
CONCLUSION
Historically, many children died with organ failure prior to the introduction of transplantation. Solid organ transplantation has revolutionized the lives of these patients, and there have been improvements in both patient and allograft survival rates through advances in medical therapies and surgical techniques. However, significant ongoing morbidities are still associated with the patients' underlying chronic conditions and transplantation. The challenge for the future is to individualize care, including tailoring immunosuppressive therapies to minimize acute and chronic allograft dysfunction and rejection and the treatment of infectious, metabolic, cardiovascular and other complications of transplantation.
REFERENCES
-
1North American Pediatric Renal Trials and Collaborative Studies. 2011 Annual Transplant Report. [30 October 2013]; Available from: https://web.emmes.com/study/ped/annlrept/annualrept2011.pdf.
» https://web.emmes.com/study/ped/annlrept/annualrept2011.pdf -
2Picascia A, Infante T, Napoli C. Luminex and antibody detection in kidney transplantation. Clin Exp Nephrol. 2012;16(3):373-81, http://dx.doi.org/10.1007/s10157-012-0635-1.
» http://dx.doi.org/10.1007/s10157-012-0635-1 -
3Henderson HT, Canter CE, Mahle WT, Dipchand AI, LaPorte K, Schechtman KB, et al. ABO-incompatible heart transplantation: analysis of the Pediatric Heart Transplant Study (PHTS) database. J Heart Lung Transplant. 2012;31(2):173-9, http://dx.doi.org/10.1016/j.healun.2011.11.013.
» http://dx.doi.org/10.1016/j.healun.2011.11.013 -
4Gelas T, McKiernan PJ, Kelly DA, Mayer DA, Mirza DF, Sharif K. ABO-incompatible pediatric liver transplantation in very small recipients: Birmingham's experience. Pediatr Transplant. 2011;15(7):706-11, http://dx.doi.org/10.1111/j.1399-3046.2011.01541.x.
» http://dx.doi.org/10.1111/j.1399-3046.2011.01541.x -
5Barnett AN, Hudson A, Hadjianastassiou VG, Marks SD, Reid CJ, Maggs TP, et al. Distribution of ABO blood group antibody titers in pediatric patients awaiting renal transplantation: implications for organ allocation policy. Transplantation. 2012;94(4):362-8, http://dx.doi.org/10.1097/TP.0b013e31825b7608.
» http://dx.doi.org/10.1097/TP.0b013e31825b7608 -
6Shishido S, Hyodo YY, Aoki Y, Takasu J, Kawamura T, Sakai KK, et al. Outcomes of pediatric ABO-incompatible kidney transplantations are equivalent to ABO-compatible controls. Transplant Proc. 2012;44(1):214-6, http://dx.doi.org/10.1016/j.transproceed.2011.12.017.
» http://dx.doi.org/10.1016/j.transproceed.2011.12.017 -
7Wu J, Ye S, Xu X, Xie H, Zhou L, Zheng S. Recipient outcomes after ABO-incompatible liver transplantation: a systematic review and meta-analysis. PloS one. 2011;6(1):e16521, http://dx.doi.org/10.1371/journal.pone.0016521.
» http://dx.doi.org/10.1371/journal.pone.0016521 -
8Asante-Korang A, Jacobs JP, Ringewald J, Carapellucci J, Rosenberg K, McKenna D, et al. Management of children undergoing cardiac transplantation with high Panel Reactive Antibodies. Cardiol Young. 2011;21 Suppl 2:124-32, http://dx.doi.org/10.1017/S1047951111001703.
» http://dx.doi.org/10.1017/S1047951111001703 -
9Mahle WT, Tresler MA, Edens RE, Rusconi P, George JF, Naftel DC, et al. Allosensitization and outcomes in pediatric heart transplantation. J Heart Lung Transplant. 2011;30(11):1221-7, http://dx.doi.org/10.1016/j.healun.2011.06.005.
» http://dx.doi.org/10.1016/j.healun.2011.06.005 -
10Wright EJ, Fiser WP, Edens RE, Frazier EA, Morrow WR, Imamura M, et al. Cardiac transplant outcomes in pediatric patients with pre-formed anti-human leukocyte antigen antibodies and/or positive retrospective crossmatch. J Heart Lung Transplant. 2007;26(11):1163-9, http://dx.doi.org/10.1016/j.healun.2007.07.042.
» http://dx.doi.org/10.1016/j.healun.2007.07.042 -
11Reinsmoen NL, Lai CH, Vo A, Jordan SC. Evolving paradigms for desensitization in managing broadly HLA sensitized transplant candidates. Discov Med. 2012;13(71):267-73.
-
12Aurora P, Edwards LB, Kucheryavaya AY, Christie JD, Dobbels F, Kirk R, et al. The Registry of the International Society for Heart and Lung Transplantation: thirteenth official pediatric lung and heart-lung transplantation report-2010. J Heart Lung Transplant. 2010;29(10):1129-41, http://dx.doi.org/10.1016/j.healun.2010.08.008.
» http://dx.doi.org/10.1016/j.healun.2010.08.008 -
13Kirk R, Edwards LB, Kucheryavaya AY, Benden C, Christie JD, Dobbels F, et al. The Registry of the International Society for Heart and Lung Transplantation: Fourteenth Pediatric Heart Transplantation Report-2011. J Heart Lung Transplant. 2011;30(10):1095-103, http://dx.doi.org/10.1016/j.healun.2011.08.005.
» http://dx.doi.org/10.1016/j.healun.2011.08.005 -
14Foster BJ, Dahhou M, Zhang X, Platt RW, Hanley JA. Change in mortality risk over time in young kidney transplant recipients. Am J Transplant. 2011;11(11):2432-42.
-
15Ng VL, Alonso EM, Bucuvalas JC, Cohen G, Limbers CA, Varni JW, et al. Health status of children alive 10 years after pediatric liver transplantation performed in the US and Canada: report of the studies of pediatric liver transplantation experience. J Pediatr. 2012;160(5):820-6 e3, http://dx.doi.org/10.1016/j.jpeds.2011.10.038.
» http://dx.doi.org/10.1016/j.jpeds.2011.10.038 -
16Webber SA, Naftel DC, Fricker FJ, Olesnevich P, Blume ED, Addonizio L, et al. Lymphoproliferative disorders after paediatric heart transplantation: a multi-institutional study. Lancet. 2006;367(9506):233-9, http://dx.doi.org/10.1016/S0140-6736(06)67933-6.
» http://dx.doi.org/10.1016/S0140-6736(06)67933-6 -
17Hocker B, Fickenscher H, Delecluse HJ, Bohm S, Kusters U, Schnitzler P, et al. Epidemiology and morbidity of Epstein-Barr virus infection in pediatric renal transplant recipients: a multicenter, prospective study. Clin Infect Dis. 2013;56(1):84-92, http://dx.doi.org/10.1093/cid/cis823.
» http://dx.doi.org/10.1093/cid/cis823 -
18Gossett JG, Canter CE, Zheng J, Schechtman K, Blume ED, Rodgers S, et al. Decline in rejection in the first year after pediatric cardiac transplantation: a multi-institutional study. The Journal of heart and lung transplantation. J Heart Lung Transplant. 2010;29(6):625-32, http://dx.doi.org/10.1016/j.healun.2009.12.009.
» http://dx.doi.org/10.1016/j.healun.2009.12.009 -
19Loupy A, Hill GS, Jordan SC. The impact of donor-specific anti-HLA antibodies on late kidney allograft failure. Nat Rev Nephrol. 2012;8(6):348-57, http://dx.doi.org/10.1038/nrneph.2012.81.
» http://dx.doi.org/10.1038/nrneph.2012.81 -
20Kfoury AG, Snow GL, Budge D, Alharethi RA, Stehlik J, Everitt MD, et al. A longitudinal study of the course of asymptomatic antibody-mediated rejection in heart transplantation. J Heart Lung Transplant. 2012;31(1):46-51, http://dx.doi.org/10.1016/j.healun.2011.10.009.
» http://dx.doi.org/10.1016/j.healun.2011.10.009 -
21Ho EK, Vlad G, Vasilescu ER, de la Torre L, Colovai AI, Burke E, et al. Pre- and posttransplantation allosensitization in heart allograft recipients: major impact of de novo alloantibody production on allograft survival. Hum Immunol. 2011;72(1):5-10, http://dx.doi.org/10.1016/j.humimm.2010.10.013.
» http://dx.doi.org/10.1016/j.humimm.2010.10.013 -
22Zarkhin V, Kambham N, Li L, Kwok S, Hsieh SC, Salvatierra O, et al. Characterization of intra-graft B cells during renal allograft rejection. Kidney Int. 2008;74(5):664-73, http://dx.doi.org/10.1038/ki.2008.249.
» http://dx.doi.org/10.1038/ki.2008.249 -
23Tsai EW, Wallace WD, Gjertson DW, Reed EF, Ettenger RB. Significance of intragraft CD138+ lymphocytes and p-S6RP in pediatric kidney transplant biopsies. Transplantation. 2010;90(8):875-81, http://dx.doi.org/10.1097/TP.0b013e3181f24e3c.
» http://dx.doi.org/10.1097/TP.0b013e3181f24e3c -
24Billing H, Rieger S, Ovens J, Susal C, Melk A, Waldherr R, et al. Successful treatment of chronic antibody-mediated rejection with IVIG and rituximab in pediatric renal transplant recipients. Transplantation. 2008;86(9):1214-21, http://dx.doi.org/10.1097/TP.0b013e3181880b35.
» http://dx.doi.org/10.1097/TP.0b013e3181880b35 -
25Miettinen J, Peräsaari J, Lauronen J, Qvist E, Valta H, Pakarinen M, et al. Donor-specific HLA antibodies and graft function in children after renal transplantation. Pediatr Nephrol. 2012;27(6):1011-9, http://dx.doi.org/10.1007/s00467-012-2101-4.
» http://dx.doi.org/10.1007/s00467-012-2101-4 -
26Honger G, Hopfer H, Arnold ML, Spriewald BM, Schaub S, Amico P. Pretransplant IgG subclasses of donor-specific human leukocyte antigen antibodies and development of antibody-mediated rejection. Transplantation. 2011;92(1):41-7, http://dx.doi.org/10.1097/TP.0b013e31821cdf0d.
» http://dx.doi.org/10.1097/TP.0b013e31821cdf0d -
27Sutherland SM, Chen G, Sequeira FA, Lou CD, Alexander SR, Tyan DB. Complement-fixing donor-specific antibodies identified by a novel C1q assay are associated with allograft loss. Pediatr Transplant. 2012;16(1):12-7, http://dx.doi.org/10.1111/j.1399-3046.2011.01599.x.
» http://dx.doi.org/10.1111/j.1399-3046.2011.01599.x -
28Everitt MD, Hammond ME, Snow GL, Stehlik J, Revelo MP, Miller DV, et al. Biopsy-diagnosed antibody-mediated rejection based on the proposed International Society for Heart and Lung Transplantation working formulation is associated with adverse cardiovascular outcomes after pediatric heart transplant. J Heart Lung Transplant.2012;31(7):686-93, http://dx.doi.org/10.1016/j.healun.2012.03.009.
» http://dx.doi.org/10.1016/j.healun.2012.03.009 -
29Ali S, Ormsby A, Shah V, Segovia MC, Kantz KL, Skorupski S, et al. Significance of complement split product C4d in ABO-compatible liver allograft: diagnosing utility in acute antibody mediated rejection. Transpl Immunol. 2012;26(1):62-9, http://dx.doi.org/10.1016/j.trim.2011.08.005.
» http://dx.doi.org/10.1016/j.trim.2011.08.005 -
30Musat AI, Agni RM, Wai PY, Pirsch JD, Lorentzen DF, Powell A, et al. The significance of donor-specific HLA antibodies in rejection and ductopenia development in ABO compatible liver transplantation. Am J Transplant. 2011;11(3):500-10.
-
31Trompeter R, Filler G, Webb NJ, Watson AR, Milford DV, Tyden G, et al. Randomized trial of tacrolimus versus cyclosporin microemulsion in renal transplantation. Pediatr. 2002;17(3):141-9.
-
32Grenda R, Watson A, Vondrak K, Webb NJ, Beattie J, Fitzpatrick M, et al. A prospective, randomized, multicenter trial of tacrolimus-based therapy with or without basiliximab in pediatric renal transplantation. Am J Transplant. 2006;6(7):1666-72.
-
33Grenda R, Watson A, Trompeter R, Tonshoff B, Jaray J, Fitzpatrick M, et al. A randomized trial to assess the impact of early steroid withdrawal on growth in pediatric renal transplantation: the TWIST study. Am J Transplant. 2010;10(4):828-36.
-
34Mazariegos GV, Steffick DE, Horslen S, Farmer D, Fryer J, Grant D, et al. Intestine transplantation in the United States, 1999-2008. Am J Transplant. 2010;10(4 Pt 2):1020-34.
-
35Fudaba Y, Spitzer TR, Shaffer J, Kawai T, Fehr T, Delmonico F, et al. Myeloma responses and tolerance following combined kidney and nonmyeloablative marrow transplantation: in vivo and in vitro analyses. Am J Transplant. 2006;6(9):2121-33.
-
36Leventhal J, Abecassis M, Miller J, Gallon L, Ravindra K, Tollerud DJ, et al. Chimerism and tolerance without GVHD or engraftment syndrome in HLA-mismatched combined kidney and hematopoietic stem cell transplantation. Sci Transl Med. 2012;4(124):124ra28.
-
37Feng S, Ekong UD, Lobritto SJ, Demetris AJ, Roberts JP, Rosenthal P, et al. Complete immunosuppression withdrawal and subsequent allograft function among pediatric recipients of parental living donor liver transplants. JAMA. 2012;307(3):283-93, http://dx.doi.org/10.1001/jama.2011.2014.
» http://dx.doi.org/10.1001/jama.2011.2014 -
38Li L, Wozniak LJ, Rodder S, Heish S, Talisetti A, Wang Q, et al. A common peripheral blood gene set for diagnosis of operational tolerance in pediatric and adult liver transplantation. Am J Transplant. 2012;12(5):1218-28.
-
39Martinez-Llordella M, Lozano JJ, Puig-Pey I, Orlando G, Tisone G, Lerut J, et al. Using transcriptional profiling to develop a diagnostic test of operational tolerance in liver transplant recipients. J Clin Invest. 2008;118(8):2845-57.
-
40Newell KA, Asare A, Kirk AD, Gisler TD, Bourcier K, Suthanthiran M, et al. Identification of a B cell signature associated with renal transplant tolerance in humans. J Clin Invest. 2010;120(6):1836-47, http://dx.doi.org/10.1172/JCI39933.
» http://dx.doi.org/10.1172/JCI39933 -
41Sagoo P, Perucha E, Sawitzki B, Tomiuk S, Stephens DA, Miqueu P, et al. Development of a cross-platform biomarker signature to detect renal transplant tolerance in humans. J Clin Invest. 2010;120(6):1848-61, http://dx.doi.org/10.1172/JCI39922.
» http://dx.doi.org/10.1172/JCI39922 -
42Filler G. Challenges in pediatric transplantation: the impact of chronic kidney disease and cardiovascular risk factors on long-term outcomes and recommended management strategies. Pediatr Transplant. 2011;15(1):25-31, http://dx.doi.org/10.1111/j.1399-3046.2010.01439.x.
» http://dx.doi.org/10.1111/j.1399-3046.2010.01439.x -
43Bullington N, Kartel J, Khoury P, Mitsnefes M. Left ventricular hypertrophy in pediatric kidney transplant recipients: long-term follow-up study. Pediatr Transplant. 2006;10(7):811-5, http://dx.doi.org/10.1111/j.1399-3046.2006.00565.x.
» http://dx.doi.org/10.1111/j.1399-3046.2006.00565.x -
44Kim GB, Kwon BS, Kang HG, Ha JW, Ha IS, Noh CI, et al. Cardiac dysfunction after renal transplantation; incomplete resolution in pediatric population. Transplantation. 2009;87(11):1737-43, http://dx.doi.org/10.1097/TP.0b013e3181a63f2f.
» http://dx.doi.org/10.1097/TP.0b013e3181a63f2f -
45Mitsnefes MM, Kimball TR, Border WL, Witt SA, Glascock BJ, Khoury PR, et al. Abnormal cardiac function in children after renal transplantation. Am J Kidney Dis. 2004;43(4):721-6.
-
46Basiratnia M, Esteghamati M, Ajami GH, Amoozgar H, Cheriki C, Soltani M, et al. Blood pressure profile in renal transplant recipients and its relation to diastolic function: tissue Doppler echocardiographic study. Pediatr Nephrol. 2011;26(3):449-57, http://dx.doi.org/10.1007/s00467-010-1724-6.
» http://dx.doi.org/10.1007/s00467-010-1724-6 -
47Mitsnefes MM, Schwartz SM, Daniels SR, Kimball TR, Khoury P, Strife CF. Changes in left ventricular mass index in children and adolescents after renal transplantation. Pediatr Transplant. 2001;5(4):279-84, http://dx.doi.org/10.1034/j.1399-3046.2001.005004279.x.
» http://dx.doi.org/10.1034/j.1399-3046.2001.005004279.x -
48Bayrakci US, Baskin E, Ozcay F, Gulleroglu K, Ozbay F, Sevmis S, et al. Abnormal circadian blood pressure regulation in liver transplanted children. Pediatr Transplant. 2012;16(2):160-4, http://dx.doi.org/10.1111/j.1399-3046.2012.01646.x.
» http://dx.doi.org/10.1111/j.1399-3046.2012.01646.x -
49McLin VA, Anand R, Daniels SR, Yin W, Alonso EM. Blood pressure elevation in long-term survivors of pediatric liver transplantation. Am J Transplant. 2012;12(1):183-90.
-
50McGlothan KR, Wyatt RJ, Ault BH, Hastings MC, Rogers T, DiSessa T, et al. Predominance of nocturnal hypertension in pediatric renal allograft recipients. Pediatr Transplant. 2006;10(5):558-64, http://dx.doi.org/10.1111/j.1399-3046.2006.00521.x.
» http://dx.doi.org/10.1111/j.1399-3046.2006.00521.x -
51Wilson AC, Greenbaum LA, Barletta GM, Chand D, Lin JJ, Patel HP, et al. High prevalence of the metabolic syndrome and associated left ventricular hypertrophy in pediatric renal transplant recipients. Pediatr Transplant. 2010;14(1):52-60, http://dx.doi.org/10.1111/j.1399-3046.2009.01141.x.
» http://dx.doi.org/10.1111/j.1399-3046.2009.01141.x -
52Goldsmith D, Pietrangeli CE. The metabolic syndrome following kidney transplantation. Kidney Int Suppl. 2010(118):S8-14, http://dx.doi.org/10.1038/ki.2010.210.
» http://dx.doi.org/10.1038/ki.2010.210 -
53Burroughs TE, Swindle JP, Salvalaggio PR, Lentine KL, Takemoto SK, Bunnapradist S, et al. Increasing incidence of new-onset diabetes after transplant among pediatric renal transplant patients. Transplantation. 2009;88(3):367-73, http://dx.doi.org/10.1097/TP.0b013e3181ae67f0.
» http://dx.doi.org/10.1097/TP.0b013e3181ae67f0 -
54Simmonds J, Dewar C, Dawkins H, Burch M, Fenton M. Tacrolimus in pediatric heart transplantation: ameliorated side effects in the steroid-free, statin era. Clin Transplant. 2009;23(3):415-9, http://dx.doi.org/10.1111/j.1399-0012.2008.00934.x.
» http://dx.doi.org/10.1111/j.1399-0012.2008.00934.x -
55Hathout E, Alonso E, Anand R, Martz K, Imseis E, Johnston J, et al. Post-transplant diabetes mellitus in pediatric liver transplantation. Pediatr Transplant. 2009;13(5):599-605, http://dx.doi.org/10.1111/j.1399-3046.2007.00603.x.
» http://dx.doi.org/10.1111/j.1399-3046.2007.00603.x -
56Filler G, Webb NJ, Milford DV, Watson AR, Gellermann J, Tyden G, et al. Four-year data after pediatric renal transplantation: a randomized trial of tacrolimus vs. cyclosporin microemulsion. Pediatr Transplant. 2005;9(4):498-503, http://dx.doi.org/10.1111/j.1399-3046.2005.00334.x.
» http://dx.doi.org/10.1111/j.1399-3046.2005.00334.x -
57Greenspan LC, Gitelman SE, Leung MA, Glidden DV, Mathias RS. Increased incidence in post-transplant diabetes mellitus in children: a case-control analysis. Pediatric Nephrol. 2002;17(1):1-5, http://dx.doi.org/10.1007/s004670200000.
» http://dx.doi.org/10.1007/s004670200000 -
58Hanevold CD, Ho PL, Talley L, Mitsnefes MM. Obesity and renal transplant outcome: A report of the North American Pediatric Renal Transplant Cooperative Study. Pediatrics. 2005;115(2):352-6, http://dx.doi.org/10.1542/peds.2004-0289.
» http://dx.doi.org/10.1542/peds.2004-0289 -
59Denburg MR, Pradhan M, Shults J, Jones A, Palmer JA, Baluarte HJ, et al. Longitudinal relations between obesity and hypertension following pediatric renal transplantation. Pediatric Nephrol. 2010;25(10):2129-39, http://dx.doi.org/10.1007/s00467-010-1572-4.
» http://dx.doi.org/10.1007/s00467-010-1572-4 -
60Perito ER, Glidden D, Roberts JP, Rosenthal P. Overweight and obesity in pediatric liver transplant recipients: prevalence and predictors before and after transplant, United Network for Organ Sharing Data, 1987-2010. Pediatr Transplant. 2012;16(1):41-9, http://dx.doi.org/10.1111/j.1399-3046.2011.01598.x.
» http://dx.doi.org/10.1111/j.1399-3046.2011.01598.x -
61Kaufman BD, Chuai S, Dobbels F, Shaddy RE. Wasting or obesity at time of transplant does not predict pediatric heart transplant outcomes: analysis of ISHLT pediatric heart transplant registry. J Heart Lung Transplant. 2009;28(12):1273-8, http://dx.doi.org/10.1016/j.healun.2009.07.020.
» http://dx.doi.org/10.1016/j.healun.2009.07.020 -
62Riella LV, Gabardi S, Chandraker A. Dyslipidemia and its therapeutic challenges in renal transplantation. Am J Transplant. 2012;12(8):1975-82.
-
63Campbell K, Ng V, Martin S, Magee J, Goebel J, Anand R, et al. Glomerular filtration rate following pediatric liver transplantation-the SPLIT experience. Am J Transplant. 2010;10(12):2673-82.
-
64Harambat J, Ranchin B, Dubourg L, Liutkus A, Hadj-Haissa A, Rivet C, et al. Renal function in pediatric liver transplantation: a long-term follow-up study. Transplantation. 2008;86(8):1028-34, http://dx.doi.org/10.1097/TP.0b013e318187748f.
» http://dx.doi.org/10.1097/TP.0b013e318187748f -
65Feingold B, Zheng J, Law YM, Morrow WR, Hoffman TM, Schechtman KB, et al. Risk factors for late renal dysfunction after pediatric heart transplantation: a multi-institutional study. Pediatr Transplant. 2011;15(7):699-705, http://dx.doi.org/10.1111/j.1399-3046.2011.01564.x.
» http://dx.doi.org/10.1111/j.1399-3046.2011.01564.x -
66Kirk R, Edwards LB, Aurora P, Taylor DO, Christie JD, Dobbels F, et al. Registry of the International Society for Heart and Lung Transplantation: Twelfth Official Pediatric Heart Transplantation Report-2009. J Heart Lung Transplant. 2009;28(10):993-1006, http://dx.doi.org/10.1016/j.healun.2009.08.008.
» http://dx.doi.org/10.1016/j.healun.2009.08.008 -
67Aurora P, Edwards LB, Christie JD, Dobbels F, Kirk R, Rahmel AO, et al. Registry of the International Society for Heart and Lung Transplantation: Twelfth Official Pediatric Lung and Heart/Lung Transplantation Report-2009. J Heart Lung Transplant. 2009;28(10):1023-30, http://dx.doi.org/10.1016/j.healun.2009.08.002.
» http://dx.doi.org/10.1016/j.healun.2009.08.002 -
68Ojo AO, Held PJ, Port FK, Wolfe RA, Leichtman AB, Young EW, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med. 2003;349(10):931-40.
-
69Grenda R, Prokurat S, Ciechanowicz A, Piatosa B, Kalicinski P. Evaluation of the genetic background of standard-immunosuppressant-related toxicity in a cohort of 200 paediatric renal allograft recipients-a retrospective study. Ann Transplant. 2009;14(3):18-24.
-
70Groetzner J, Kaczmarek I, Schulz U, Stegemann E, Kaiser K, Wittwer T, et al. Mycophenolate and sirolimus as calcineurin inhibitor-free immunosuppression improves renal function better than calcineurin inhibitor-reduction in late cardiac transplant recipients with chronic renal failure. Transplantation. 2009;87(5):726-33, http://dx.doi.org/10.1097/TP.0b013e3181963371.
» http://dx.doi.org/10.1097/TP.0b013e3181963371 -
71Mourer JS, Hartigh J, van Zwet EW, Mallat MJ, Dubbeld J, de Fijter JW. Randomized trial comparing late concentration-controlled calcineurin inhibitor or mycophenolate mofetil withdrawal. Transplantation. 2012;93(9):887-94, http://dx.doi.org/10.1097/TP.0b013e31824ad60a.
» http://dx.doi.org/10.1097/TP.0b013e31824ad60a -
72Krischock L, Gullett A, Bockenhauer D, Rees L, Trompeter RS, Marks SD. Calcineurin-inhibitor free immunosuppression with mycophenolate mofetil and corticosteroids in paediatric renal transplantation improves renal allograft function without increasing acute rejection. Pediatr Transplant. 2009;13(4):475-81, http://dx.doi.org/10.1111/j.1399-3046.2008.01031.x.
» http://dx.doi.org/10.1111/j.1399-3046.2008.01031.x -
73Hocker B, Tonshoff B. Calcineurin inhibitor-free immunosuppression in pediatric renal transplantation: a viable option? Paediatr drugs. 2011;13(1):49-69.
-
74Flechner SM, Kobashigawa J, Klintmalm G. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity. Clin Transplant. 2008;22(1):1-15.
-
75Weintraub L, Li L, Kambham N, Alexander S, Concepcion W, Miller K, et al. Patient selection critical for calcineurin inhibitor withdrawal in pediatric kidney transplantation. Pediatr Transplant. 2008;12(5):541-9, http://dx.doi.org/10.1111/j.1399-3046.2007.00847.x.
» http://dx.doi.org/10.1111/j.1399-3046.2007.00847.x -
76Hazzan M, Labalette M, Copin MC, Glowacki F, Provot F, Pruv FR, et al. Predictive factors of acute rejection after early cyclosporine withdrawal in renal transplant recipients who receive mycophenolate mofetil: results from a prospective, randomized trial. J Am Soc Nephrol. 2005;16(8):2509-16, http://dx.doi.org/10.1681/ASN.2005030312.
» http://dx.doi.org/10.1681/ASN.2005030312 -
77Tonshoff B, David-Neto E, Ettenger R, Filler G, van Gelder T, Goebel J, et al. Pediatric aspects of therapeutic drug monitoring of mycophenolic acid in renal transplantation. Transplantation Rev (Orlando). 2011;25(2):78-89, http://dx.doi.org/10.1016/j.trre.2011.01.001.
» http://dx.doi.org/10.1016/j.trre.2011.01.001 -
78Hymes LC, Warshaw BL. Five-year experience using sirolimus-based, calcineurin inhibitor-free immunosuppression in pediatric renal transplantation. Pediatr Transplant. 2011;15(4):437-41, http://dx.doi.org/10.1111/j.1399-3046.2011.01477.x.
» http://dx.doi.org/10.1111/j.1399-3046.2011.01477.x -
79Dell-Olio D, Kelly DA. Calcineurin inhibitor minimization in pediatric liver allograft recipients. Pediatr Transplant. 2009;13(6):670-81, http://dx.doi.org/10.1111/j.1399-3046.2009.01184.x.
» http://dx.doi.org/10.1111/j.1399-3046.2009.01184.x -
80Vincenti F, Charpentier B, Vanrenterghem Y, Rostaing L, Bresnahan B, Darji P, et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant. 2010;10(3):535-46.
-
81Broyer M, Le Bihan C, Charbit M, Guest G, Tete MJ, Gagnadoux MF, et al. Long-term social outcome of children after kidney transplantation. Transplantation. 2004;77(7):1033-7, http://dx.doi.org/10.1097/01.TP.0000120947.75697.8B.
» http://dx.doi.org/10.1097/01.TP.0000120947.75697.8B -
82Alonso EM, Shepherd R, Martz KL, Yin W, Anand R. Linear growth patterns in prepubertal children following liver transplantation. Am J Transplant. 2009;9(6):1389-97.
-
83Sarwal MM, Ettenger RB, Dharnidharka V, Benfield M, Mathias R, Portale A, et al. Complete steroid avoidance is effective and safe in children with renal transplants: a multicenter randomized trial with three-year follow-up. Am J Transplant. 2012;12(10):2719-29.
-
84Klare B, Montoya CR, Fischer DC, Stangl MJ, Haffner D. Normal adult height after steroid-withdrawal within 6 months of pediatric kidney transplantation: a 20 years single center experience. Transpl Int. 2012;25(3):276-82, http://dx.doi.org/10.1111/j.1432-2277.2011.01400.x.
» http://dx.doi.org/10.1111/j.1432-2277.2011.01400.x -
85Delucchi A, Valenzuela M, Lillo AM, Guerrero JL, Cano F, Azocar M, et al. Early steroid withdrawal in pediatric renal transplant: five years of follow-up. Pediatric Nephrol. 2011;26(12):2235-44, http://dx.doi.org/10.1007/s00467-011-1934-6.
» http://dx.doi.org/10.1007/s00467-011-1934-6 -
86Hocker B, Weber LT, Feneberg R, Drube J, John U, Fehrenbach H, et al. Improved growth and cardiovascular risk after late steroid withdrawal: 2-year results of a prospective, randomised trial in paediatric renal transplantation. Nephrol Dial Transplant. 2010;25(2):617-24, http://dx.doi.org/10.1093/ndt/gfp506.
» http://dx.doi.org/10.1093/ndt/gfp506 -
87Diem HV, Sokal EM, Janssen M, Otte JB, Reding R. Steroid withdrawal after pediatric liver transplantation: a long-term follow-up study in 109 recipients. Transplantation. 2003;75(10):1664-70, http://dx.doi.org/10.1097/01.TP.0000063938.49112.C2.
» http://dx.doi.org/10.1097/01.TP.0000063938.49112.C2 -
88Hodson EM, Willis NS, Craig JC. Growth hormone for children with chronic kidney disease. Cochrane Database Syst Rev. 2012;2:CD003264.
-
89Gil S, Vaiani E, Guercio G, Ciaccio M, Turconi A, Delgado N, et al. Effectiveness of rhGH treatment on final height of renal-transplant recipients in childhood. Pediatric Nephrol. 2012;27(6):1005-9, http://dx.doi.org/10.1007/s00467-011-2090-8.
» http://dx.doi.org/10.1007/s00467-011-2090-8 -
90Rees L, Shroff R, Hutchinson C, Fernando ON, Trompeter RS. Long-term outcome of paediatric renal transplantation: follow-up of 300 children from 1973 to 2000. Nephron Clin Pract. 2007;105(2):c68-76, http://dx.doi.org/10.1159/000097601.
» http://dx.doi.org/10.1159/000097601 -
91Shroff R, Knott C, Gullett A, Wells D, Marks SD, Rees L. Vitamin D deficiency is associated with short stature and may influence blood pressure control in paediatric renal transplant recipients. Pediatric Nephrol. 2011;26(12):2227-33, http://dx.doi.org/10.1007/s00467-011-1920-z.
» http://dx.doi.org/10.1007/s00467-011-1920-z -
92Tainio J, Qvist E, Vehmas R, Jahnukainen K, Holtta T, Valta H, et al. Pubertal development is normal in adolescents after renal transplantation in childhood. Transplantation. 2011;92(4):404-9, http://dx.doi.org/10.1097/TP.0b013e3182247bd5.
» http://dx.doi.org/10.1097/TP.0b013e3182247bd5 -
93El Moghazy WM, Ogura Y, Harada K, Koizumi A, Uemoto S. Can children catch up in growth after living donor liver transplantation? Liver Transpl. 2010;16(4):453-60.
-
94Gras JM, Gerkens S, Beguin C, Janssen M, Smets F, Otte JB, et al. Steroid-free, tacrolimus-basiliximab immunosuppression in pediatric liver transplantation: clinical and pharmacoeconomic study in 50 children. Liver Transpl. 2008;14(4):469-77, http://dx.doi.org/10.1002/lt.21397.
» http://dx.doi.org/10.1002/lt.21397 -
95Peterson RE, Perens GS, Alejos JC, Wetzel GT, Chang RK. Growth and weight gain of prepubertal children after cardiac transplantation. Pediatr Transplant. 2008;12(4):436-41, http://dx.doi.org/10.1111/j.1399-3046.2007.00826.x.
» http://dx.doi.org/10.1111/j.1399-3046.2007.00826.x -
96Lacaille F, Vass N, Sauvat F, Canioni D, Colomb V, Talbotec C, et al. Long-term outcome, growth and digestive function in children 2 to 18 years after intestinal transplantation. Gut. 2008;57(4):455-61.
-
97Eiser C, Morse R. Quality-of-life measures in chronic diseases of childhood. Health Technol Assess. 2001;5(4):1-157.
-
98Karrfelt HM, Berg UB. Long-term psychosocial outcome after renal transplantation during childhood. Pediatr Transplant. 2008;12(5):557-62, http://dx.doi.org/10.1111/j.1399-3046.2007.00859.x.
» http://dx.doi.org/10.1111/j.1399-3046.2007.00859.x -
99Sundaram SS, Landgraf JM, Neighbors K, Cohn RA, Alonso EM. Adolescent health-related quality of life following liver and kidney transplantation. Am J Transplant. 2007;7(4):982-9.
-
100Bartosh SM, Leverson G, Robillard D, Sollinger HW. Long-term outcomes in pediatric renal transplant recipients who survive into adulthood. Transplantation. 2003;76(8):1195-200, http://dx.doi.org/10.1097/01.TP.0000092524.75807.84.
» http://dx.doi.org/10.1097/01.TP.0000092524.75807.84 -
101Qvist E, Narhi V, Apajasalo M, Ronnholm K, Jalanko H, Almqvist F, et al. Psychosocial adjustment and quality of life after renal transplantation in early childhood. Pediatr Transplant. 2004;8(2):120-5, http://dx.doi.org/10.1046/j.1399-3046.2003.00121.x.
» http://dx.doi.org/10.1046/j.1399-3046.2003.00121.x -
102Anthony SJ, Hebert D, Todd L, Korus M, Langlois V, Pool R, et al. Child and parental perspectives of multidimensional quality of life outcomes after kidney transplantation. Pediatr Transplant. 2010;14(2):249-56, http://dx.doi.org/10.1111/j.1399-3046.2009.01214.x.
» http://dx.doi.org/10.1111/j.1399-3046.2009.01214.x -
103Falger J, Landolt MA, Latal B, Ruth EM, Neuhaus TJ, Laube GF. Outcome after renal transplantation. Part II: quality of life and psychosocial adjustment. Pediatric Nephrology. 2008;23(8):1347-54.
-
104Noohi S, Khaghani-Zadeh M, Javadipour M, Assari S, Najafi M, Ebrahiminia M, et al. Anxiety and depression are correlated with higher morbidity after kidney transplantation. Transplant Proc. 2007;39(4):1074-8, http://dx.doi.org/10.1016/j.transproceed.2007.04.002.
» http://dx.doi.org/10.1016/j.transproceed.2007.04.002 -
105Berney-Martinet S, Key F, Bell L, Lepine S, Clermont MJ, Fombonne E. Psychological profile of adolescents with a kidney transplant. Pediatr Transplant. 2009;13(6):701-10, http://dx.doi.org/10.1111/j.1399-3046.2008.01053.x.
» http://dx.doi.org/10.1111/j.1399-3046.2008.01053.x -
106Alonso EM, Limbers CA, Neighbors K, Martz K, Bucuvalas JC, Webb T, et al. Cross-sectional analysis of health-related quality of life in pediatric liver transplant recipients. J Pediatr. 2010;156(2):270-6 e1, http://dx.doi.org/10.1016/j.jpeds.2009.08.048.
» http://dx.doi.org/10.1016/j.jpeds.2009.08.048 -
107Alonso EM, Neighbors K, Barton FB, McDiarmid SV, Dunn SP, Mazariegos GV, et al. Health-related quality of life and family function following pediatric liver transplantation. Liver Transpl. 2008 Apr;14(4):460-8, http://dx.doi.org/10.1002/lt.21352.
» http://dx.doi.org/10.1002/lt.21352 -
108Uzark KC, Sauer SN, Lawrence KS, Miller J, Addonizio L, Crowley DC. The psychosocial impact of pediatric heart transplantation. J Heart Lung Transplant. 1992;11(6):1160-7.
-
109Sigfusson G, Fricker FJ, Bernstein D, Addonizio LJ, Baum D, Hsu DT, et al. Long-term survivors of pediatric heart transplantation: a multicenter report of sixty-eight children who have survived longer than five years. J Pediatr. 1997;130(6):862-71, http://dx.doi.org/10.1016/S0022-3476(97)70270-1.
» http://dx.doi.org/10.1016/S0022-3476(97)70270-1 -
110Green A, McSweeney J, Ainley K, Bryant J. In my shoes: children's quality of life after heart transplantation. Prog Transplant. 2007 Sep;17(3):199-207; quiz 208.
-
111Ross M, Kouretas P, Gamberg P, Miller J, Burge M, Reitz B, et al. Ten-and 20-year survivors of pediatric orthotopic heart transplantation. J Heart Lung Transplant.2006;25(3):261-70, http://dx.doi.org/10.1016/j.healun.2005.09.011.
» http://dx.doi.org/10.1016/j.healun.2005.09.011 -
112DeMaso DR, Twente AW, Spratt EG, O'Brien P. Impact of psychologic functioning, medical severity, and family functioning in pediatric heart transplantation. J Heart Lung Transplant. 1995;14(6 Pt 1):1102-8.
-
113Wray J, Radley-Smith R. Longitudinal assessment of psychological functioning in children after heart or heart-lung transplantation. J Heart Lung Transplant. 2006;25(3):345-52, http://dx.doi.org/10.1016/j.healun.2005.09.018.
» http://dx.doi.org/10.1016/j.healun.2005.09.018 -
114Wray J, Radley-Smith R. Beyond the first year after pediatric heart or heart-lung transplantation: Changes in cognitive function and behaviour. Pediatr Transplant. 2005;9(2):170-7, http://dx.doi.org/10.1111/j.1399-3046.2005.00265.x.
» http://dx.doi.org/10.1111/j.1399-3046.2005.00265.x -
115Lanuza DM, Lefaiver CA, Farcas GA. Research on the quality of life of lung transplant candidates and recipients: an integrative review. Heart Lung. 2000;29(3):180-95.
-
116Lanuza DM, Lefaiver C, Mc Cabe M, Farcas GA, Garrity E, Jr. Prospective study of functional status and quality of life before and after lung transplantation. Chest. 2000;118(1):115-22, http://dx.doi.org/10.1378/chest.118.1.115.
» http://dx.doi.org/10.1378/chest.118.1.115 -
117Gross CR, Savik K, Bolman RM, 3rd, Hertz MI. Long-term health status and quality of life outcomes of lung transplant recipients. Chest. 1995;108(6):1587-93, http://dx.doi.org/10.1378/chest.108.6.1587.
» http://dx.doi.org/10.1378/chest.108.6.1587 -
118Smeritschnig B, Jaksch P, Kocher A, Seebacher G, Aigner C, Mazhar S, et al. Quality of life after lung transplantation: a cross-sectional study. J Heart Lung Transplant. 2005;24(4):474-80, http://dx.doi.org/10.1016/j.healun.2003.12.013.
» http://dx.doi.org/10.1016/j.healun.2003.12.013 -
119Myaskovsky L, Posluszny DM, Schulz R, DiMartini AF, Switzer GE, DeVito Dabbs A, et al. Predictors and outcomes of health-related quality of life in caregivers of cardiothoracic transplant recipients. Am J Transplant. 2012;12(12):3387-97.
-
120Sudan D, Horslen S, Botha J, Grant W, Torres C, Shaw B, et al. Quality of life after pediatric intestinal transplantation: the perception of pediatric recipients and their parents. Am J Transplant. 2004;4(3):407-13.
-
121Ngo KD, Farmer DG, McDiarmid SV, Artavia K, Ament ME, Vargas J, et al. Pediatric health-related quality of life after intestinal transplantation. Pediatr Transplant. 2011;15(8):849-54, http://dx.doi.org/10.1111/j.1399-3046.2011.01590.x.
» http://dx.doi.org/10.1111/j.1399-3046.2011.01590.x -
122Abu-Elmagd KM, Kosmach-Park B, Costa G, Zenati M, Martin L, Koritsky DA, et al. Long-term survival, nutritional autonomy, and quality of life after intestinal and multivisceral transplantation. Ann Surg. 2012;256(3):494-508, http://dx.doi.org/10.1097/SLA.0b013e318265f310.
» http://dx.doi.org/10.1097/SLA.0b013e318265f310 -
123Taylor RM, Franck LS, Gibson F, Donaldson N, Dhawan A. Study of the factors affecting health-related quality of life in adolescents after liver transplantation. Am J Transplant. 2009;9(5):1179-88.
-
124Young GS, Mintzer LL, Seacord D, Castaneda M, Mesrkhani V, Stuber ML. Symptoms of posttraumatic stress disorder in parents of transplant recipients: incidence, severity, and related factors. Pediatrics. 2003;111(6 Pt 1):e725-31, http://dx.doi.org/10.1542/peds.111.6.e725",-1,"xxx/6.e725.
» http://dx.doi.org/10.1542/peds.111.6.e725",-1,"xxx/6.e725 -
125Farley LM, DeMaso DR, D'Angelo E, Kinnamon C, Bastardi H, Hill CE, et al. Parenting stress and parental post-traumatic stress disorder in families after pediatric heart transplantation. J Heart Lung Transplant. 2007;26(2):120-6, http://dx.doi.org/10.1016/j.healun.2006.11.013.
» http://dx.doi.org/10.1016/j.healun.2006.11.013 -
126Qvist E, Pihko H, Fagerudd P, Valanne L, Lamminranta S, Karikoski J, et al. Neurodevelopmental outcome in high-risk patients after renal transplantation in early childhood. Pediatr Transplant. 2002;6(1):53-62, http://dx.doi.org/10.1034/j.1399-3046.2002.1o040.x.
» http://dx.doi.org/10.1034/j.1399-3046.2002.1o040.x -
127Motoyama O, Kawamura T, Aikawa A, Hasegawa A, Iitaka K. Head circumference and development in young children after renal transplantation. Pediatr Int. 2009;51(1):71-4, http://dx.doi.org/10.1111/j.1442-200X.2008.02653.x.
» http://dx.doi.org/10.1111/j.1442-200X.2008.02653.x -
128Sorensen LG, Neighbors K, Martz K, Zelko F, Bucuvalas JC, Alonso EM. Cognitive and academic outcomes after pediatric liver transplantation: Functional Outcomes Group (FOG) results. Am J Transplant. 2011;11(2):303-11.
-
129Kaller T, Schulz KH, Sander K, Boeck A, Rogiers X, Burdelski M. Cognitive abilities in children after liver transplantation. Transplantation. 2005;79(9):1252-6, http://dx.doi.org/10.1097/01.TP.0000161251.20520.42.
» http://dx.doi.org/10.1097/01.TP.0000161251.20520.42 -
130Chinnock RE, Freier MC, Ashwal S, Pivonka-Jones J, Shankel T, Cutler D, et al. Developmental outcomes after pediatric heart transplantation. J Heart Lung Transplant. 2008;27(10):1079-84, http://dx.doi.org/10.1016/j.healun.2008.07.012.
» http://dx.doi.org/10.1016/j.healun.2008.07.012 -
131Harden PN, Walsh G, Bandler N, Bradley S, Lonsdale D, Taylor J, et al. Bridging the gap: an integrated paediatric to adult clinical service for young adults with kidney failure. BMJ. 2012;344:e3718, http://dx.doi.org/10.1136/bmj.e3718",-1,"xxx/bmj.e3718.
» http://dx.doi.org/10.1136/bmj.e3718",-1,"xxx/bmj.e3718
-
No potential conflict of interest was reported.
Publication Dates
-
Publication in this collection
Jan 2014